Image Description

INVESTORS
& MEDIA

circle

PRESS RELEASES

  • Webcast Image Webcast
    X Q2 2018 Cytokinetics, Inc. Earnings Conference Call
    Jul 26, 2018 4:30 PM EDT

    Q2 2018 Cytokinetics, Inc. Earnings Conference Call
    Jul 26, 2018 4:30 PM EDT
Date Title and Summary
Toggle Summary Cytokinetics to Announce Second Quarter Results on July 26, 2018
SOUTH SAN FRANCISCO, Calif. , July 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report second quarter results on July 26, 2018 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy Presented at the 2018 Annual Cure SMA Conference
First Study of Muscle-Directed Therapy in Patients with SMA Showed Potentially Clinically Meaningful Effects on Six Minute Walk Distance and Maximal Expiratory Pressure SOUTH SAN FRANCISCO, Calif. , June 16, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced data from
Toggle Summary Cytokinetics to Present at the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif. , June 13, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018 at
Toggle Summary Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy to be Presented at the 2018 Annual Cure SMA Conference on June 16, 2018
SOUTH SAN FRANCISCO, Calif. , June 08, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented in an oral presentation at the 2018 Annual Cure SMA
Toggle Summary Cytokinetics and Cure SMA Renew and Expand Partnership to Advance Education and Awareness of SMA
ELK GROVE VILLAGE, Ill. and SOUTH SAN FRANCISCO, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Cure SMA and Cytokinetics today announced an expanded partnership to increase education, awareness and fundraising for spinal muscular atrophy (SMA).  As a National Platinum Partner for 2018, Cytokinetics will
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 16, 2018 at 10:30 AM Pacific Time at the Embassy Suites Hotel , located at 250 Gateway Boulevard in South
Toggle Summary Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
SOUTH SAN FRANCISCO, Calif. and WASHINGTON, May 01, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is renewing its Gold Level Sponsorship of the National Walks to
Toggle Summary Cytokinetics, Inc. Reports First Quarter 2018 Financial Results
Completed Enrollment in Phase 2 Study of Reldesemtiv in Patients with SMA; Data Expected in Q2 2018 Preparing to Initiate Second Phase 3 Clinical Trial of Omecamtiv Mecarbil SOUTH SAN FRANCISCO, Calif. , April 26, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) reported financial
Toggle Summary Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference
SOUTH SAN FRANCISCO, Calif. , April 24, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented by John Day , M.D., Ph.D., Professor of Neurology and
Toggle Summary Cytokinetics to Announce First Quarter Results on April 26, 2018
SOUTH SAN FRANCISCO, Calif. , April 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report first quarter results on April 26, 2018 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics to Present at March Investor Conferences
SOUTH SAN FRANCISCO, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences: Cowen and Company 38 th
Toggle Summary Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq:CYTK) today announced that it is joining the global initiative to raise awareness of Rare Disease Day®, an international campaign led by the European Organisation for Rare Diseases (EURORDIS) and the
Toggle Summary Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results
  Company Provides 2018 Financial Guidance and Expected Milestones;  Reduced Operating Expenses vs. 2017; Over Two Years of Cash Based on Current Burn Rate CK-2127107 Advancing in Four Clinical Trials Under Collaboration with Astellas; Results Expected in 2018 with Data from Phase 2 Clinical Trial
Toggle Summary Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the RBC Capital Markets Global Healthcare Conference on Thursday, February 22,
Toggle Summary Cytokinetics Names Robert Califf, M.D., to Board of Directors
Appointment Strengthens Regulatory, Global Clinical Research and Cardiology Expertise as Company Advances Its Development Pipeline and Executes Against Its Vision 2020 SOUTH SAN FRANCISCO, Calif. , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq:CYTK) today announced that
Toggle Summary Cytokinetics to Announce Fourth Quarter Results on February 15, 2018
SOUTH SAN FRANCISCO, Calif. , Feb. 02, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report fourth quarter results on February 15, 2018 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Announces Progress Against Vision 2020
Multiple Clinical Trials Advance Under Collaborations with Astellas and Amgen Results from Four Clinical Trials of CK-2127107 Expected in 2018 Pipeline Expands with Three New Programs Advancing from Muscle Biology Research to Development SOUTH SAN FRANCISCO, Calif. , Jan.
Toggle Summary Cytokinetics Announces Presentation of Results From VITALITY-ALS at 28th International Symposium on ALS/MND
Previously Announced Results from Phase 3 Clinical Trial of Tirasemtiv Shared with ALS Community VITALITY-ALS Did Not Meet Primary or Secondary Endpoints Trial Informs Development of Next Generation Drug Candidate SOUTH SAN FRANCISCO, Calif. , Dec. 08, 2017 (GLOBE NEWSWIRE) -- Cytokinetics,
Toggle Summary Cytokinetics Announces Results of VITALITY-ALS to be Presented at the International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif. , Dec. 01, 2017 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq:CYTK) today announced that the results from VITALITY-ALS ( V entilatory I nvestigation of T irasemtiv and A ssessment of L ongitudinal I ndices after T reatment for a Y ear in ALS ), the
Toggle Summary New Publication Shows Respiratory Decline Correlated With Disease Progression in People Living With ALS
Retrospective Analyses of Clinical Trials in ALS Shows Faster Rate of Decline in Slow Vital Capacity Strongly Predicts Increased Risk of Future Clinical Events SOUTH SAN FRANCISCO, Calif. , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the publication of
Toggle Summary New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability and Amplification of Skeletal Muscle Response to Nerve Activation
Next Generation Fast Skeletal Muscle Activator Appears Promising Compared to Tirasemtiv in Studies of Healthy Volunteers SOUTH SAN FRANCISCO, Calif. , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the publication of results from three double-blind,
Toggle Summary Cytokinetics Announces Negative Results From VITALITY-ALS
Phase 3 Clinical Trial of Tirasemtiv in Patients with ALS Did Not Meet Primary or Secondary Endpoints Results to be Presented December 8 th at 28th International Symposium on ALS/MND Conference Call Today at 8:30 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov.
Toggle Summary Cytokinetics Announces Additional Results From COSMIC-HF at the American Heart Association Scientific Sessions 2017
SOUTH SAN FRANCISCO, Calif. , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic  O ral  S tudy of  M yosin Activation to  I ncrease  C ontractility in  H eart  F ailure), a Phase 2 clinical trial evaluating 
Toggle Summary Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the American Heart Association Scientific Sessions 2017
SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2017 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic  O ral  S tudy of  M yosin Activation to  I ncrease  C ontractility in  H eart  F ailure), a Phase 2 trial evaluating 
Toggle Summary Cytokinetics, Inc. Reports Third Quarter 2017 Financial Results
VITALITY-ALS Proceeding towards Planned Database Lock and Read-out in Q4; Commercial Planning and Preparations for Potential Regulatory Submissions Underway CK-2127107 Advancing in Four Mid-Stage Clinical Trials Under Collaboration with Astellas First Patient Recently Dosed in Japan in GALACTIC-HF
Toggle Summary Cytokinetics to Announce Third Quarter Results on October 26, 2017
SOUTH SAN FRANCISCO, Calif. , Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report third quarter results on October 26, 2017 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Announces Dosing of First Patient in Japan in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
Company Earns $10 Million Milestone Payment from Amgen SOUTH SAN FRANCISCO, Calif. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that the first patient has been dosed in Japan in GALACTIC-HF ( G lobal A pproach to L owering A dverse C ardiac Outcomes
Toggle Summary Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA 21st Annual Scientific Meeting
Effects of Omecamtiv Mecarbil Were Similar in Patients with Ischemic and Non-Ischemic Heart Failure SOUTH SAN FRANCISCO, Calif. , Sept. 18, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin
Toggle Summary Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the HFSA 21st Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C ontractility in H eart F ailure), a Phase 2 trial evaluating omecamtiv mecarbil in
Toggle Summary Cytokinetics to Present at September Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences: Morgan Stanley 15 th Annual Global
Toggle Summary Cytokinetics, Inc. Reports Second Quarter 2017 Financial Results
Results Expected from VITALITY-ALS, Our Phase 3 Clinical Trial of Tirasemtiv, in Q4 2017 CK-2127107 Advancing in Four Clinical Trials Under Our Collaboration with Astellas Omecamtiv Mecarbil Phase 3 Clinical Trial Proceeding on Plan in GALACTIC-HF Under Our Collaboration with Amgen SOUTH SAN
Toggle Summary Cytokinetics Announces Positive Results From Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Patients With Heart Failure
Data Supports Inclusion of Japan in GALACTIC-HF Company is Eligible to Earn $10 Million Milestone Payment from Amgen upon First Patient Dosing in Japan in Phase 3 Outcomes Trial SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced
Toggle Summary Cytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, Calif. , July 27, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the start of FORTITUDE-ALS, F unctional O utcomes in a R andomized T rial of I nvestigational T reatment with CK-2127107 to U nderstand D ecline in E ndpoints – in ALS.
Toggle Summary Cytokinetics to Announce Second Quarter Results on August 2, 2017
SOUTH SAN FRANCISCO, Calif. , July 26, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is scheduled to report second quarter results on Wednesday, August 2, 2017 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Announces Baseline Data From First Cohort of Phase 2 Clinical Trial of CK-2127107 in Patients With SMA
Patient Demographics Presented at Cure SMA 2017 Annual SMA Conference SOUTH SAN FRANCISCO, Calif. , July 05, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that data relating to patient baseline characteristics and the reasons for patient screen failure, both from the
Toggle Summary Cytokinetics Announces Start of Phase 1b Clinical Trial of CK-2127107 in Elderly Subjects With Limited Mobility
Trial Designed to Assess Effects of Skeletal Muscle Activation on Measures of Muscle Strength and Endurance Under Collaboration with Astellas SOUTH SAN FRANCISCO, Calif. , June 29, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the start of a Phase 1b,
Toggle Summary Cytokinetics Announces Presentations at the Cure SMA 2017 Annual SMA Conference
SOUTH SAN FRANCISCO, Calif. , June 23, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced presentations at the Cure SMA 2017 Annual SMA Conference from June 29 - July 2, 2017 in Orlando, FL. In an oral presentation on July 1 , Stacy Rudnicki , M.D., Director, Clinical
Toggle Summary Cytokinetics to Participate in Panel on Neuromuscular Disorders at the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif. , June 13, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to participate in a panel discussion on Neuromuscular Disorders at the JMP Securities 2017 Life Sciences
Toggle Summary Cytokinetics Announces Orphan Drug Designation for CK-2127107 for the Treatment of Spinal Muscular Atrophy
SOUTH SAN FRANCISCO, Calif. , May 15, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration ( FDA ) has granted orphan drug designation to CK-2127107 for the potential treatment of
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif. , May 11, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that its Annual Meeting of Stockholders will be held on Thursday, May 18, 2017 at 10:30 AM Pacific Time at the Embassy Suites Hotel , located at 250 Gateway Boulevard in South San
Toggle Summary Cytokinetics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. , May 08, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the pricing of an underwritten public offering of 5,260,000 shares of its common stock at a price to the public of $14.25 per share, before underwriting discounts and commissions.
Toggle Summary Cytokinetics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. , May 08, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced plans to offer, subject to market and other conditions, $75,000,000 of its common stock in an underwritten public offering. There can be no assurance as to whether or when the
Toggle Summary Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
SOUTH SAN FRANCISCO, Calif., and WASHINGTON, May 03, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS which includes Cytokinetics’ renewal of its Gold Level Sponsorship of the National
Toggle Summary Cytokinetics Announces Results from Dose Escalation Phase of COSMIC-HF Presented at Heart Failure 2017
SOUTH SAN FRANCISCO, Calif. , May 01, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that results from the dose escalation phase of COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C ontractility in H eart F ailure), a Phase 2 trial evaluating
Toggle Summary Cytokinetics, Inc. Reports First Quarter 2017 Financial Results
Data Monitoring Committee for VITALITY-ALS Recommended Continuation of Phase 3 Trial; Results Expected in Q4 Sale of Royalty on Omecamtiv Mecarbil to Royalty Pharma  Contributed to Increased Cash Balance Expansion of Clinical Trials Program for CK-2127107 in Collaboration with Astellas SOUTH SAN
Toggle Summary Cytokinetics Added to S&P SmallCap 600
SOUTH SAN FRANCISCO, Calif. , April 21, 2017 (GLOBE NEWSWIRE) -- Cytokinetics (Nasdaq:CYTK) today announced it has been selected for addition to the S&P SmallCap 600 GICS Biotechnology Sub-Industry Index. The index, a member of the Dow Jones Total Stock Market Indices family, is designed to
Toggle Summary Cytokinetics to Announce First Quarter Results on April 27, 2017
SOUTH SAN FRANCISCO, Calif. , April 13, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is scheduled to report first quarter results on Thursday, April 27, 2017 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics to Present at the 16th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , March 29, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the 16 th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at
Toggle Summary Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy
Data Monitoring Committee Agrees to Proceed to Higher Dose Cohort One of Four Clinical Trials in 2017 under Astellas Collaboration SOUTH SAN FRANCISCO, Calif. , March 29, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that the second cohort of the Phase 2 clinical trial
Toggle Summary Origent Data Sciences and Cytokinetics Advance Collaboration Intended to Validate Predictive Analytics Model in ALS
Research Aimed at Accelerating Conduct of Clinical Trials VIENNA, Va. AND SOUTH SAN FRANCISCO, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- Origent Data Sciences, Inc. (Origent) and Cytokinetics, Inc. (Nasdaq:CYTK) today announced the advancement of their research collaboration to prospectively
Toggle Summary Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference
Next-Generation Fast Skeletal Troponin Activator Improves Muscle Function in Mouse Models of Spinal Muscular Atrophy SOUTH SAN FRANCISCO, Calif. , March 22, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that preclinical data for CK-2127107 were presented at the MDA
Toggle Summary Cytokinetics Announces Additional Results From COSMIC-HF Presented at ACC.17
SOUTH SAN FRANCISCO, Calif. , March 20, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C ontractility in H eart F ailure), a Phase 2 trial evaluating omecamtiv mecarbil in
Toggle Summary Cytokinetics Announces Presentation of Additional Results from COSMIC-HF at ACC.17
SOUTH SAN FRANCISCO, Calif. , March 06, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C ontractility in H eart F ailure), a Phase 2 trial evaluating omecamtiv mecarbil in
Toggle Summary Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is joining the global initiative with the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to raise awareness of Rare
Toggle Summary Cytokinetics to Present at March Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences: Cowen and Company 37 th  Annual Health Care
Toggle Summary Cytokinetics, Inc. Reports Fourth Quarter 2016 Financial Results
Company Provides 2017 Financial Guidance and Expected Milestones Phase 3 Results Expected from VITALITY-ALS in Q4 2017 SOUTH SAN FRANCISCO, Calif. , Feb. 16, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) reported total revenues for the fourth quarter of 2016 were $33.1 million ,
Toggle Summary Cytokinetics to Announce Fourth Quarter Results on February 16, 2017
SOUTH SAN FRANCISCO, Calif. , Feb. 03, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is scheduled to report fourth quarter results on Thursday, February 16, 2017 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics and Royalty Pharma Announce $100 Million Transaction for Omecamtiv Mecarbil
Royalty Pharma Buys 4.5 Percent Royalty on Worldwide Sales for $90 Million Plus $10 Million Equity in Cytokinetics Cytokinetics Agrees to Exercise Option to Co-Fund Phase 3 Development Program Under Collaboration with Amgen for Increased Royalty and Co-Promotion Rights in North America Company to
Toggle Summary Cytokinetics Added to Nasdaq Biotechnology Index
SOUTH SAN FRANCISCO, Calif. , Dec. 16, 2016 (GLOBE NEWSWIRE) -- Cytokinetics (Nasdaq:CYTK) today announced it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI). The addition will take effect as part of the annual re-ranking of the NBI upon market open on Monday, December
Toggle Summary Cytokinetics Announces New Data Presented at the International Symposium on ALS/MND
Patient Baseline Characteristics from VITALITY-ALS Comparable to BENEFIT-ALS Physician Survey Shows Regional Variability in Use of Noninvasive Ventilation SOUTH SAN FRANCISCO, Calif. , Dec. 09, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that new data was presented at
Toggle Summary Origent Data Sciences and Cytokinetics Present Analyses Demonstrating Baseline Data Predict Measures of Vital Capacity in Patients With ALS
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Origent Data Sciences, Inc. (Origent) and Cytokinetics, Inc. (Nasdaq:CYTK) today announced results from the first part of a research collaboration to refine and prospectively validate an Origent computer model to predict the course of
Toggle Summary Cytokinetics Announces Presentations at the International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif. , Dec. 02, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced one oral presentation and two poster presentations at the 27th International Symposium on ALS/MND in Dublin, Ireland . The posters will be presented on Wednesday, December 7, 2016 , and
Toggle Summary Cytokinetics Announces Start of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil
Trial to be Conducted Under Special Protocol Assessment with the FDA Company Earns $26.7 Million Milestone Payment from Amgen SOUTH SAN FRANCISCO, Calif. , Dec. 01, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the activation of the first clinical site and the start of
Toggle Summary The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function in Patients With Chronic Heart Failure
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Cytokinetics, Inc. (NASDAQ:CYTK) today announced The Lancet published results from a Phase 2 clinical trial evaluating omecamtiv mecarbil in patients with chronic heart failure.
Toggle Summary Cytokinetics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Nov. 22, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present at the 28 th Annual Piper Jaffray Healthcare Conference on November 30, 2016 at 12:00 PM ET at the
Toggle Summary Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the AHA Annual Scientific Meeting
Data Show Omecamtiv Mecarbil Improved Measures of Left Atrial Structure and Function SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C
Toggle Summary Cytokinetics Announces New Results From COSMIC-HF to be Presented at the American Heart Association Scientific Sessions 2016
SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2016 (GLOBE NEWSWIRE) -- Cytokinetics , (Nasdaq:CYTK) today announced that a new analysis of left atrial structure and function from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C ontractility in H eart F ailure), a Phase 2 trial
Toggle Summary Cytokinetics Announces Publication Relating to Novel Smooth Muscle Myosin Inhibitor
Discovery of Novel Binding Mechanism Has Potential to Guide Design of Myosin Inhibitors SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) a leader in muscle biology and the mechanics of muscle performance, today announced the publication of preclinical
Toggle Summary Cytokinetics, Inc. Reports Third Quarter 2016 Financial Results
Omecamtiv Mecarbil Advancing to Phase 3 With Agreement from FDA  on Key Elements of Special Protocol Assessment VIGOR-ALS Enrolling Patients with ALS Who Have Completed VITALITY-ALS $65 Million Recently Received From Astellas Related to Expanded Collaboration SOUTH SAN FRANCISCO, Calif. , Oct.
Toggle Summary Cytokinetics Announces First Patient Enrolled in VIGOR-ALS, an Open-Label Extension Clinical Trial of Tirasemtiv
Eligible Patients Have Completed Participation in Phase 3 Clinical Trial VITALITY-ALS SOUTH SAN FRANCISCO, Calif. , Oct. 18, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the first patient has been enrolled in VIGOR-ALS ( V entilatory I nvestigations in G lobal O
Toggle Summary Cytokinetics to Announce Third Quarter Results on October 27, 2016
SOUTH SAN FRANCISCO, Calif. , Oct. 13, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is scheduled to report third quarter results on Thursday, October 27, 2016 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Announces Early Termination of Hart-Scott-Rodino Waiting Period for Expanded Collaboration With Astellas
Clearance Triggers $65 Million Upfront Cash Payment in Addition to $30 Million in Sponsored Research & Development Funding Through 2017 SOUTH SAN FRANCISCO, Calif. , Sept. 29, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that the Federal Trade Commission has granted
Toggle Summary Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA Annual Scientific Meeting
Data Show Treatment with Omecamtiv Mecarbil May Improve Patient Symptoms at 20 Weeks SOUTH SAN FRANCISCO, Calif. , Sept. 19, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C
Toggle Summary Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the HFSA Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif. , Sept. 09, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C ontractility in H eart F ailure), a Phase 2 trial evaluating omecamtiv mecarbil in
Toggle Summary Cytokinetics Announces Next-Generation Fast Skeletal Muscle Activator Entering IND-Enabling Studies
Triggers Milestone Payment from Astellas;  Expands Portfolio of Skeletal Muscle Activators SOUTH SAN FRANCISCO, Calif. , Sept. 08, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the initiation of IND-enabling studies for a next-generation fast skeletal muscle activator
Toggle Summary Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development
Company Expects the Initiation of Phase 3 Cardiovascular Outcomes Clinical Trial in Q4 2016 SOUTH SAN FRANCISCO, Calif. , Sept. 01, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the advancement of omecamtiv mecarbil to Phase 3 clinical development with a cardiovascular
Toggle Summary Cytokinetics Completes Enrollment in VITALITY-ALS, Phase 3 Clinical Trial of Tirasemtiv in Patients With ALS
Results Expected 2H 2017; Open-Label Extension Trial to Begin in Q4 2016 SOUTH SAN FRANCISCO, Calif. , Aug. 17, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the completion of patient enrollment in VITALITY-ALS ( V entilatory I nvestigation of T irasemtiv and A ssessment
Toggle Summary Cytokinetics, Inc. Reports Second Quarter 2016 Financial Results
Company Recently Announced Option Right for Tirasemtiv  and Expansion of Global Collaboration for CK-2127107 in ALS with Astellas   Nearing Completion of Patient Enrollment in VITALITY-ALS SOUTH SAN FRANCISCO, Calif. , July 28, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc.
Toggle Summary Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS
SOUTH SAN FRANCISCO, Calif. and WASHINGTON, July 27, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) and The ALS Association today announced the continuation and expansion of their partnership in the fight against ALS, including Cytokinetics' renewal of its Gold Level Sponsorship of the
Toggle Summary Cytokinetics and Astellas Announce Option Right for Tirasemtiv and Expansion of Global Collaboration for CK-2127107 in ALS
Cytokinetics to Receive $65 Million in Upfront Payments and $30 Million in Additional Sponsored R&D; Potential for More than $100 Million in Payments Associated with the Exercise of the Option SOUTH SAN FRANCISCO, Calif. and TOKYO, July 27, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc.
Toggle Summary Cytokinetics to Announce Second Quarter Results on July 28, 2016
SOUTH SAN FRANCISCO, Calif. , July 14, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that it is scheduled to report second quarter results on Thursday, July 28, 2016 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , July 05, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at Cantor Fitzgerald’s 2 nd Annual Healthcare Conference on Tuesday, July 12, 2016
Toggle Summary Cytokinetics Announces Start of Phase 2 Clinical Trial of CK-2127107 in Patients With Chronic Obstructive Pulmonary Disease
 Trial Designed to Assess Effect of Skeletal Muscle Activation to Increase Physical Function and Exercise Tolerance Under Collaboration with Astellas SOUTH SAN FRANCISCO, Calif. , June 30, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the start of a randomized,
Toggle Summary Cytokinetics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , June 14, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum , President and Chief Executive Officer, is scheduled to present at the JMP Securities 2016 Life Sciences Conference on June 21, 2016 at 1:00 PM EDT at the St.
Toggle Summary Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress
Treatment with Omecamtiv Mecarbil Produced Progressive and Sustained Effects  On Cardiac Function as Measured by Reductions in Diastolic Ventricular Volume and NT-proBNP SOUTH SAN FRANCISCO, Calif. , May 23, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc.
Toggle Summary Cytokinetics Appoints Edward M. Kaye, M.D., to Board of Directors
SOUTH SAN FRANCISCO, Calif. , May 20, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Edward M. Kaye , M.D., has been appointed to the company’s Board of Directors. Dr. Kaye is the Interim Chief Executive Officer and Senior Vice President, Chief Medical Officer of
Toggle Summary Cytokinetics Announces Additional COSMIC-HF Results to Be Presented at Heart Failure 2016
SOUTH SAN FRANCISCO, Calif. , May 13, 2016 (GLOBE NEWSWIRE) -- Cytokinetics , (Nasdaq:CYTK) announced today that a poster presentation on additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2b trial evaluating omecamtiv
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif. , May 11, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that its Annual Meeting of Stockholders will be held on Wednesday, May 18, 2016 at 10:30 AM Pacific Time at the Embassy Suites Hotel , located at 250 Gateway Boulevard in South San
Toggle Summary Cytokinetics to Ring Nasdaq Closing Bell to Launch ALS Awareness Month
Company Leadership Joins The ALS Association to Raise Awareness, Education and Funding for People With ALS and Their Caregivers SOUTH SAN FRANCISCO, Calif. , May 02, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it will ring the Closing Bell at Nasdaq this afternoon
Toggle Summary Cytokinetics, Inc. Reports First Quarter 2016 Financial Results
VITALITY-ALS on Track to Complete Patient Enrollment in 1H 2016 SOUTH SAN FRANCISCO, Calif. , April 28, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) reported total research and development revenues for the first quarter of 2016 were $8.4 million , compared to $4.4 million , during the
Toggle Summary Cytokinetics to Announce First Quarter Results on April 28, 2016
SOUTH SAN FRANCISCO, Calif. , April 14, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that it is scheduled to report first quarter results on Thursday, April 28, 2016 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics to Present at the 15th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , April 05, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the 15 th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at
Toggle Summary Cytokinetics Announces Start of Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure
SOUTH SAN FRANCISCO, Calif. , April 04, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the start of a double-blind, randomized, placebo-controlled, multi-center Phase 2 clinical trial to evaluate the safety, pharmacokinetics and efficacy of omecamtiv mecarbil in Japanese
Toggle Summary Origent Data Sciences and Cytokinetics Announce Research Collaboration on Predictive Analytics Model in ALS
Origent Receives ALS Association Grant to Enable Research Partnership SOUTH SAN FRANCISCO, Calif., March 31, 2016 (GLOBE NEWSWIRE) -- Origent Data Sciences, Inc. (Origent) and Cytokinetics, Inc. (Nasdaq:CYTK) today announced a research collaboration to refine and prospectively validate an Origent
Toggle Summary Cytokinetics to Present at March Investor Conferences
SOUTH SAN FRANCISCO, Calif. , March 01, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences: Cowen and Company 36 th Annual Health Care
Toggle Summary Cytokinetics Joins Global Movement to Recognize International Rare Disease Day
SOUTH SAN FRANCISCO, Calif. , Feb. 29, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is joining forces with the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to raise awareness of Rare Disease Day®, an
Toggle Summary Cytokinetics, Inc. Reports Fourth Quarter 2015 Financial Results
Company Provides 2016 Financial Guidance and Expected Milestones SOUTH SAN FRANCISCO, Calif. , Feb. 16, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) reported total research and development revenues for the fourth quarter of 2015 were $9.8 million , compared to $21.8 million , which
Toggle Summary Cytokinetics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Feb. 03, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum , President and Chief Executive Officer, is scheduled to present at the 18 th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 at 1:30 PM EST at
Toggle Summary Cytokinetics to Announce Fourth Quarter Results on February 16, 2016
SOUTH SAN FRANCISCO, Calif. , Feb. 02, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that it is scheduled to report fourth quarter results on Tuesday, February 16, 2016 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Outlines Vision 2020 Strategic Initiative to Advance Portfolio of Muscle Biology Drug Candidates
SOUTH SAN FRANCISCO, Calif. , Jan. 11, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today outlined Vision 2020: Empowering Our Future, a strategic initiative designed to deepen and expand its pipeline over the next five years as well as advance a portfolio of muscle-biology directed
Toggle Summary Cytokinetics Presents Analyses Demonstrating Predictive Value of Slow Vital Capacity for Clinical Outcomes in ALS
SOUTH SAN FRANCISCO, Calif. , Jan. 10, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the presentation of exploratory analyses of data from EMPOWER, a Phase 3 clinical trial of dexpramipexole in patients with ALS, which demonstrated the rate of decline of slow vital
Toggle Summary Cytokinetics Announces Start of Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy
Company Initiates Phase 2 Program Under Collaboration With Astellas SOUTH SAN FRANCISCO, Calif. , Jan. 04, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that its first Phase 2 clinical trial of CK-2127107, a novel fast skeletal muscle troponin activator, in patients with
Toggle Summary Cure SMA and Cytokinetics Announce Partnership to Advance Education and Awareness of Spinal Muscular Atrophy
ELK GROVE VILLAGE, Ill. and SOUTH SAN FRANCISCO, Calif., Dec. 08, 2015 (GLOBE NEWSWIRE) -- Cure SMA and Cytokinetics Inc. (Nasdaq:CYTK), a leading muscle biology company, today announced an expanded partnership to increase education, awareness and fundraising for spinal muscular atrophy (SMA).
Toggle Summary Cytokinetics to Present at 27th Annual Piper Jaffray Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 24, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that Robert I. Blum , President and Chief Executive Officer, is scheduled to present at the 27 th Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2015 at 10:00
Toggle Summary Amgen and Cytokinetics Announce Late-Breaking Presentation of COSMIC-HF Trial at AHA Scientific Sessions 2015
First Chronic Dosing Trial of Oral Omecamtiv Mecarbil Showed Statistically Significant Improvements in Several Pre-Specified Measures of Cardiac Function and Volumes THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 08, 2015 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Cytokinetics
Toggle Summary Cytokinetics Announces Results From COSMIC-HF to be Presented in Late Breaking Clinical Trial Session at American Heart Association Scientific Sessions
Company to Host Investor Meeting & Webcast Monday, November 9 at 7 a.m. ET SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2015 (GLOBE NEWSWIRE) -- Cytokinetics Incorporated (NASDAQ:CYTK) today announced that results from the expansion phase of COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to
Toggle Summary Cytokinetics, Inc. Reports Third Quarter 2015 Financial Results
Recently Announced Positive Top-line Results From COSMIC-HF; Data Demonstrated Statistically Significant Improvements in Several Pre-Specified Measures of Cardiac Function Company Lowers 2015 R&D Expense Guidance SOUTH SAN FRANCISCO, Calif. , Oct. 29, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Inc.
Toggle Summary Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, a Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure
Data Showed Statistically Significant Improvements in Several Pre-Specified Measures of Cardiac Function THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Oct. 27, 2015 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Cytokinetics Incorporated (NASDAQ:CYTK) today announced that data from the
Toggle Summary Cytokinetics to Announce Third Quarter Results on October 29, 2015
SOUTH SAN FRANCISCO, Calif. , Oct. 15, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that it is scheduled to report third quarter results on Thursday, October 29, 2015 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics, Inc. Reports Second Quarter 2015 Financial Results
Company Recently Started VITALITY-ALS; Results from COSMIC-HF Expected in Q4 Company Updates Financial Guidance for 2015 SOUTH SAN FRANCISCO, Calif. , July 29, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) reported total research and development revenues for the second quarter of 2015
Toggle Summary Cytokinetics to Announce Second Quarter Results on July 29, 2015
SOUTH SAN FRANCISCO, Calif. , July 15, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that it is scheduled to report second quarter results on Wednesday, July 29, 2015 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Announces Start of Phase 3 Clinical Trial of Tirasemtiv in Patients With ALS
VITALITY-ALS is Designed to Confirm and Extend Results Observed in Phase 2b Trial SOUTH SAN FRANCISCO, Calif. , July 14, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK), a leading muscle biology company, today announced the start of VITALITY-ALS (Ventilatory Investigation of Tirasemtiv
Toggle Summary Cytokinetics and the ALS Association Announce Awarding of Grant for Phase 3 Clinical Trial and Biomarker Research Collaboration
Proceeds From Ice Bucket Challenge Used to Support a Unique Collaboration Between Non-Profit, Academia and Industry SOUTH SAN FRANCISCO, Calif. and WASHINGTON, DC, July 14, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. , (Nasdaq:CYTK) and The ALS Association today announced that The Association has
Toggle Summary Cytokinetics Presents Results From Phase I Studies of CK-2127107
Novel Fast Skeletal Muscle Activator Demonstrated Increases in Skeletal Muscle Force; Data Support Progression to Phase II SOUTH SAN FRANCISCO, Calif. , June 19, 2015 (GLOBE NEWSWIRE) -- Cytokinetics (Nasdaq:CYTK) announced today that results from three double-blind, randomized, placebo-controlled
Toggle Summary Cytokinetics to Present at the 9th Annual JMP Securities Life Sciences Conference 2015
SOUTH SAN FRANCISCO, Calif. , June 16, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the 9 th Annual JMP Securities Life Sciences Conference 2015 on
Toggle Summary Cytokinetics Announces Poster Presentation on CK-2127107 at the 19th International SMA Researcher Meeting
SOUTH SAN FRANCISCO, Calif. , June 11, 2015 (GLOBE NEWSWIRE) -- Cytokinetics , (Nasdaq:CYTK) announced today that a poster presentation on the company’s fast skeletal muscle activator, CK-2127107, will be presented at the 19 th International SMA Researcher Meeting to be held during the 2015 Annual
Toggle Summary Cytokinetics and The ALS Association Announce Partnership to Advance the Fight Against ALS
Company Expands National and Regional Sponsorships SOUTH SAN FRANCISCO, Calif. and WASHINGTON D.C. , June 4, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif. , May 13, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that its Annual Meeting of Stockholders will be held on Wednesday, May 20, 2015 at 10:30 AM Pacific Time at the Embassy Suites Hotel , located at 250 Gateway Boulevard in South
Toggle Summary Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results
Company is Readying to Initiate a Phase III Clinical Trial of Tirasemtiv in Patients With ALS following Recent Meetings With FDA and EMA Completion of Patient Enrollment in COSMIC-HF Enable Results Expected Later This Year SOUTH SAN FRANCISCO, Calif. , April 30, 2015 (GLOBE NEWSWIRE) --
Toggle Summary Cytokinetics to Announce First Quarter Results on April 30, 2015
South San Francisco, CA., April 16, 2015, - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report first quarter results on Thursday, April 30, 2015 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at
Toggle Summary Cytokinetics to Host R&D Day on Tuesday, May 12, 2015
Senior Management Team to Provide Updates on Drug Discovery and Development Programs Key Opinion Leaders in Neuromuscular Diseases and Heart Failure to Provide Commentary and Perspectives South San Francisco, CA, April 13, 2015 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is
Toggle Summary Cytokinetics to Present at the 14th Annual Needham Healthcare Conference
South San Francisco, CA, April 8, 2015 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 14 th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 11:20 AM at
Toggle Summary Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis
Data from Evidence of Effect Trial Provide Support for Novel Mechanism of Action in Neuromuscular Diseases South San Francisco, CA, March 25, 2015 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication of a manuscript relating to its fast skeletal muscle troponin activator
Toggle Summary Cytokinetics Announces Completion of Enrollment in COSMIC-HF
Results Expected Later This Year to Inform Potential Progression of Omecamtiv Mecarbil to Phase III SOUTH SAN FRANCISCO, CA, March 13, 2015 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C ontractility in H eart
Toggle Summary Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases
SOUTH SAN FRANCISCO, CA, February 27, 2015 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is joining forces on February 28 with patients and health care advocates in the United States and globally to raise awareness for Rare Disease Day ® .  Rare Disease Day is dedicated to
Toggle Summary Cytokinetics Announces Publication of Preclinical Data Relating to CK-2127107 and Exercise Tolerance in Rodent Model of Heart Failure
Manuscript Supports Rationale for Development of CK-2127107 in Diseases Associated with Muscle Weakness and Fatigue South San Francisco, CA, February 26, 2015 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication of a manuscript relating to its fast skeletal muscle troponin
Toggle Summary Cytokinetics to Present at Healthcare Conferences in March
South San Francisco, CA, February 24, 2015 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following healthcare conferences: Cowen and Company 35 th Annual Health Care
Toggle Summary Cytokinetics, Incorporated Reports Fourth Quarter 2014 Financial Results
Ongoing Regulatory Interactions in US and Europe Inform Progression of Tirasemtiv to Phase III COSMIC-HF Nears Completion of Enrollment with Results Expected Later This Year Company Exceeded Financial Guidance in 2014 and Provides Milestones and Financial Guidance for 2015 SOUTH SAN FRANCISCO, CA,
Toggle Summary Cytokinetics to Announce Fourth Quarter Results on February 12, 2015
South San Francisco, CA., January 29, 2015, - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report fourth quarter results on Thursday, February 12, 2015 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference
Toggle Summary Cytokinetics and Astellas Announce Expansion of Collaboration for Development of CK-2127107 in Spinal Muscular Atrophy and Other Neuromuscular Indications
Cytokinetics Expects to Receive Over $75 Million in Committed Capital and Reimbursements For Planned Activities   Companies Plan to Initiate Phase II Clinical Trial in 2015 South San Francisco, CA, and Tokyo, December 23, 2014 - Cytokinetics, Incorporated (NASDAQ:CYTK) and Astellas Pharma
Toggle Summary Cytokinetics Announces Presentations Relating to Tirasemtiv and Effects on Respiratory Muscle Function at International Symposium on ALS/MND
South San Francisco, CA, December 5, 2014 - Cytokinetics, (Nasdaq: CYTK) announced today that an oral presentation and four poster presentations relating to tirasemtiv were presented at the 25 th International Symposium on ALS/MND held at the Square Brussels Meeting Centre in Brussels, Belgium. 
Toggle Summary Cytokinetics Announces Presentations Relating to Tirasemtiv at the 25th International Symposium on ALS/MND
South San Francisco, CA, December 1, 2014 - Cytokinetics, (Nasdaq: CYTK) announced today that presentations relating to tirasemtiv are scheduled during  the 25 th International Symposium on ALS/MND to be held December 5-7, 2014 at the Square Brussels Meeting Centre in Brussels, Belgium.  Tirasemtiv
Toggle Summary Cytokinetics to Participate in the 26th Annual Piper Jaffray Healthcare Conference
South San Francisco, CA, November 26, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a panel presentation during the upcoming 26th Annual Piper Jaffray Healthcare Conference.
Toggle Summary Cytokinetics' President & CEO Robert Blum Receives 2014 Lou Gehrig Iron Horse Award From ALS Therapy Development Institute
SOUTH SAN FRANCISCO, CA, November 10, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that the Company's President and CEO, Robert Blum, received the 2014 Lou Gehrig Iron Horse Award from ALS Therapy Development Institute (ALS.net) at the Fourth Annual A White Coat Affair Gala on
Toggle Summary Cytokinetics, Incorporated Reports Third Quarter 2014 Financial Results
Company Provides Updates on the Advancement of Development Programs Focused to Muscle Biology SOUTH SAN FRANCISCO, CA, October 30, 2014   -  Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and development revenues for the third quarter of 2014 were $9.4 million, compared to $4.5
Toggle Summary Cytokinetics Provides Development Program Update for Omecamtiv Mecarbil
Over 275 Patients Enrolled in COSMIC-HF; Data Monitoring Committee Recommends Continuation with No Changes to the Protocol Phase I Pharmacokinetic and Safety Study Comparing Japanese and Caucasian Volunteers Completed SOUTH SAN FRANCISCO, CA, October 27, 2014 - Cytokinetics, Incorporated (Nasdaq:
Toggle Summary Cytokinetics Provides Development Program Update for Tirasemtiv
Robust Effects of Tirasemtiv on Slow Vital Capacity Observed in BENEFIT-ALS Support Progression to Phase III Company Believes Effects on Slow Vital Capacity Could Support Registration Path For Tirasemtiv SOUTH SAN FRANCISCO, CA, October 20, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) provided
Toggle Summary Cytokinetics to Announce Third Quarter Results on October 30, 2014
South San Francisco, CA., October 16, 2014, - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report third quarter results on Thursday, October 30, 2014 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call
Toggle Summary Cytokinetics Announces Development Program Update for CK-2127107
Company Completes Program of Five Phase I Clinical Trials Pursuant to Agreed Development Plan with Astellas South San Francisco, CA, October 13, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced the completion of five Phase I clinical trials evaluating CK-2127107 in healthy volunteers, and
Toggle Summary Cytokinetics to Present at the 34th Annual Canaccord Global Growth Conference
South San Francisco, CA, August 7, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 34 th Annual Canaccord Global Health Conference on August 14, 2014 at 10:30 AM Eastern
Toggle Summary Cytokinetics, Incorporated Reports Second Quarter 2014 Financial Results
Company Provides Updates to Development Programs Focused to Muscle Biology SOUTH SAN FRANCISCO, CA, July 30, 2014   -  Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and development revenues for the second quarter of 2014 were $7.8 million, compared to $1.0 million during the
Toggle Summary Cytokinetics to Announce Second Quarter Results on July 30, 2014
South San Francisco, CA., July 16, 2014, - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report second quarter results on Wednesday, July 30, 2014 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at
Toggle Summary Cytokinetics Announced Additional Results Relating to Tirasemtiv from Pre-Specificed Subgroup Analyses of BENEFIT-ALS
Effects of Tirasemtiv on Slow Vital Capacity During 12 Weeks of Double-Blind Treatment Were Observed Consistently Across Patient Subgroups SOUTH SAN FRANCISCO, CA, July 10, 2014  -  Cytokinetics, Incorporated (Nasdaq: CYTK) announced that additional results from BENEFIT-ALS ( B
Toggle Summary Cytokinetics Announces Additional Data from BENEFIT-ALS to be Presented at the 13th International Congress on Neuromuscular Diseases
South San Francisco, CA, July 3, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that additional data from BENEFIT-ALS ( B linded  E valuation of  N euromuscular  E ffects and  F unctional  I mprovement with  T irasemtiv in AL S) will be presented during a poster presentation
Toggle Summary Cytokinetics Announces Data Relating to Tirasemtiv Presented at the 2014 Annual Spinal Muscular Atrophy Conference
Tirasemtiv Demonstrates Improvements in Muscle Force, Grip Strength and Resistance to Fatigue in Preclinical Models South San Francisco, CA, June 13, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced that data from preclinical research relating to tirasemtiv in mouse models of spinal
Toggle Summary Cytokinetics Announces Two Presentations Relating to Tirasemtiv to be Presented at the 2014 Annual Spinal Muscular Atrophy Conference
South San Francisco, CA, June 6, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that two presentations relating to tirasemtiv are scheduled to be presented at the 2014 Annual Spinal Muscular Atrophy Conference from June 12-15, 2014 at the Gaylord National Resort in National
Toggle Summary Cytokinetics Announces Further Results from BENEFIT-ALS Relating to Effects Following Withdrawal of Tirasemtiv
Effects of Tirasemtiv on Slow Vital Capacity during 12 Weeks of Double-Blind Treatment Were Maintained through 4 Weeks after the Last Dose of Double-Blind Treatment South San Francisco, CA, June 2, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that additional results from
Toggle Summary Cytokinetics to Present at Upcoming Healthcare Conferences
South San Francisco, CA, May 28, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that members of its management team are scheduled to participate at the following healthcare conferences:  Jefferies Global Healthcare Conference Date:  Wednesday, June 4 th Time:  8:30 AM Eastern
Toggle Summary Cytokinetics Announces Additional Data From BENEFIT-ALS to be Presented at the Joint Congress of European Neurology
South San Francisco, CA, May 27, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that additional data from BENEFIT-ALS ( B linded  E valuation of  N euromuscular  E ffects and  F unctional  I mprovement with  T irasemtiv in AL S) will be presented during an oral presentation
Toggle Summary Cytokinetics Announces Three Publications Relating to Tirasemtiv and the Impact of Skeletal Muscle Activation on Respiratory Function and Muscle Strength
Manuscripts Support Rationale for  Potential Further Development of Tirasemtiv in Patients Living with ALS South San Francisco, CA, May 21, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced the recent publication of three peer-reviewed manuscripts relating to tirasemtiv and fast
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
South San Francisco, CA., May 15, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that its Annual Meeting of Stockholders will be held on Wednesday, May 21, 2014 at 3:00 PM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San Francisco, CA. 
Toggle Summary Cytokinetics, Incorporated Reports First Quarter 2014 Financial Results
Company Considers Potential Next Steps for First-in-Class Skeletal Muscle Activator Focused to ALS Partnered and Funded Programs Advancing Through Clinical Trials in Parallel SOUTH SAN FRANCISCO, CA, May 6, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported total revenues of $8.0 million for
Toggle Summary Cytokinetics Announces Additional Results from BENEFIT-ALS
First Clinical Trial in Patients with ALS to Show a Significant Reduction in Decline of Slow Vital Capacity Adverse Events on Tirasemtiv May Have Confounded Primary Efficacy Results  and Warrant Additional Analyses to Inform Potential Continued Development SOUTH SAN FRANCISCO, CA,
Toggle Summary Cytokinetics Announces Top-Line Results From BENEFIT-ALS
Company Summarizes Initial Data From Phase IIb Clinical Trial of Tirasemtiv No Effect on Primary Efficacy Endpoint; Mixed Effects on Secondary Endpoints SOUTH SAN FRANCISCO, CA, April 25, 2014   -  Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the top-line results of
Toggle Summary Cytokinetics to Announce First Quarter Results on May 6, 2014
South San Francisco, CA., April 24, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report first quarter results on Tuesday, May 6, 2014 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30
Toggle Summary Cytokinetics to Host Investor Breakfast and Webcast Following Presentation of Results from BENEFIT-ALS
South San Francisco, CA, April 23, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it plans to host an Investor Breakfast and Webcast on the morning following the presentation of the results from the BENEFIT-ALS trial at the 66 th Annual Meeting of the American Academy of
Toggle Summary Cytokinetics Announces Results From BENEFIT-ALS Will Be Presented at the 66th Annual Meeting of the American Academy of Neurology
South San Francisco, CA, April 22, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that results from BENEFIT-ALS ( B linded  E valuation of  N euromuscular  E ffects and  F unctional  I mprovement with  T irasemtiv in AL S) will be presented during a Platform Session scheduled at
Toggle Summary Cytokinetics to Present at the 13th Annual Needham Healthcare Conference
South San Francisco, CA, April 1, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014 at 1:40 PM Eastern Daylight Time at the
Toggle Summary Cytokinetics Announces the Opening to Enrollment of the Expansion of COSMIC-HF
Commencement of Next Stage in International Phase II Clinical Trial  of Oral Formulation of Omecamtiv Mecarbil in Patients with Heart Failure South San Francisco, CA, March 28, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that the expansion phase of the COSMIC-HF ( C hronic
Toggle Summary Cytokinetics Announces Initiation of Multiple Dose Phase I Clinical Trial of CK-2127107
Commencement of Study Triggers Milestone Payment from Astellas   South San Francisco, CA, March 27, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced the initiation of an additional Phase I clinical trial of CK-2127107, a fast skeletal muscle troponin activator.
Toggle Summary Cytokinetics to Present at Upcoming Healthcare Conferences
South San Francisco, CA, February 28, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that members of its management team are scheduled to participate at the following healthcare conferences:  Cowen and Company 34th Annual Health Care Conference Date:  Monday, March 3rd Time:
Toggle Summary Cytokinetics Announces Closing of its Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares
  South San Francisco, CA, February 25, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the closing of  its previously announced underwritten public offering of 4,375,000 shares of its common stock, as well as 656,250 additional shares of its common stock pursuant to the full
Toggle Summary Cytokinetics Announces pricing of $35.0 Million Public Offering of Common Stock
South San Francisco, CA, February 20, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the pricing of its previously announced underwritten public offering of 4,375,000 shares of its common stock at a price to the public of $8.00 per share.
Toggle Summary Cytokinetics Announces Proposed Public Offering of Common Stock
South San Francisco, CA, February 19, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it intends to offer and sell shares of its common stock in an underwritten public offering.  Cytokinetics also expects to grant the underwriters an option to purchase up to an additional 15%
Toggle Summary Cytokinetics, Incorporated Reports Fourth Quarter 2013 Financial Results
Company Summarizes Recent Progress in Development Programs and Provides Expected Milestones and Financial Guidance for 2014 SOUTH SAN FRANCISCO, CA, February 6, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported total revenues of $24.3 million for the fourth quarter of 2013, compared to $2.2
Toggle Summary Cytokinetics to Present at Upcoming Healthcare Conferences
South San Francisco, CA, February 4, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that members of its management team are scheduled to participate at the following healthcare conferences:   BIO CEO & Investor Conference Date:  Tuesday, February 11 th Time:  10:00 AM Eastern
Toggle Summary Cytokinetics to Announce Fourth Quarter Results on February 6, 2014
South San Francisco, CA., January 23, 2014, - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report fourth quarter results on Thursday, February 6, 2014 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference
Toggle Summary Cytokinetics Provides Updates Regarding Clinical Development Program for Omecamtiv Mecarbil
Protocol for COSMIC-HF Amended to Evaluate Dose Titration Strategy Preparations Underway for Phase I Pharmacokinetic Trial in Japanese Volunteers South San Francisco, CA, January 13, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) provided updates today regarding COSMIC-HF ( C hronic O ral S tudy
Toggle Summary Cytokinetics Announces Results from First-Time-In-Humans Clinical Trial of CK-2127107 at Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders
CK-2127107 Appears Well-Tolerated with Linear Dose-Proportional Pharmacokinetics in Phase I Clinical Trial South San Francisco, CA, December 10, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that the results from a first-time-in-humans clinical trial of CK-2127107 in healthy male
Toggle Summary Cytokinetics Announces Presentation Providing Update on BENEFIT-ALS at International Symposium on ALS/MND
Interim, Blinded, Aggregate Data on Patient Enrollment, Baseline Demographics, Dose Escalation and Tolerability Presented; Final Results Expected in Second Quarter of 2014 South San Francisco, CA, December 8, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that a platform
Toggle Summary Cytokinetics to Present Data Related to Skeletal Muscle Activators at Conference of Society on Sarcopenia, Cachexia and Wasting Disorders
South San Francisco, CA, December 4, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that two presentations, relating to its fast skeletal muscle troponin activators, are scheduled to be presented at the 7 th International Conference of the Society on Sarcopenia, Cachexia and
Toggle Summary Cytokinetics Announces Closing of Enrollment Into BENEFIT-ALS, A Phase IIb Clinical Trial of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis
Results Are Expected in First Half of 2014   South San Francisco, CA, December 3, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the company has closed recruitment and enrollment of patients into BENEFIT-ALS ( B linded E valuation of N euromuscular E ffects and F unctional I
Toggle Summary Cytokinetics Announces Presentation Relating to Tirasemtiv and BENEFIT-ALS at International Symposium on ALS/MND
South San Francisco, CA, December 2, 2013 - Cytokinetics, (Nasdaq: CYTK) announced today that a presentation relating to tirasemtiv and BENEFIT-ALS, is scheduled to be presented at the 24 th International Symposium on ALS/MND to be held December 6-8, 2013 at the Atahotel Quark in Milan, Italy.
Toggle Summary Cytokinetics to Present at the 25th Annual Piper Jaffray Healthcare Conference
South San Francisco, CA, November 26, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 25 th Annual Piper Jaffray Healthcare Conference on December 3, 2013 at 9:30 AM
Toggle Summary Cytokinetics, Incorporated Reports Third Quarter 2013 Financial Results
Company Provides Updates on Key Progress in Development Programs for Heart Failure and ALS SOUTH SAN FRANCISCO, CA, October 30, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported total revenues for the third quarter of 2013 were $4.5 million, compared to $1.7 million during the same period
Toggle Summary Cytokinetics to Announce Third Quarter Results on October 30, 2013
South San Francisco, CA., October 16, 2013, - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report third quarter results on Wednesday, October 30, 2013 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference
Toggle Summary Cytokinetics to Present at the Leerink Swann Rare Disease Roundtable
South San Francisco, CA, September 27, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Leerink Swann Rare Disease Roundtable on October 2, 2013 at 9:40 AM at Le Parker
Toggle Summary Cytokinetics Announces Presentation of Data from ATOMIC-AHF at Heart Failure Society of America Annual Scientific Meeting
Additional Safety and Pharmacodynamic Results Presented in Late Breaking Clinical Trials Session South San Francisco, CA, September 23, 2013 - Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the presentation of additional data from the ATOMIC-AHF ( A cute T reatment with O mecamtiv M
Toggle Summary Cytokinetics to Present at Healthcare Conferences in September
South San Francisco, CA, September 4, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following healthcare conferences: Morgan Stanley Global Healthcare Conference Date:
Toggle Summary Amgen and Cytokinetics Announce the First Presentation of Data from Phase 2 ATOMIC-AHF Study of Omecamtiv Mecarbil
    First Trial to Evaluate Cardiac Myosin Activator in Patients with Acute Heart Failure Presented at ESC Congress 2013 THOUSAND OAKS, Calif. and South San Francisco, Calif. (Sept. 2, 2013) - Amgen (NASDAQ:AMGN) and Cytokinetics Incorporated (NASDAQ:CYTK) today announced the first
Toggle Summary Cytokinetics Announces Publication of Results from Phase II Trials of Tirasemtiv in Patients with ALS
  Manuscripts Support the Design and Conduct of the Ongoing BENEFIT-ALS Trial South San Francisco, CA, August 22, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication of two manuscripts reporting data from two clinical trials of tirasemtiv , a novel mechanism fast
Toggle Summary Cytokinetics to Host Investor Event Following Presentation of Results from ATOMIC-AHF at the European Society of Cardiology Congress 2013
South San Francisco, CA, August 14, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today its plans to host an Investor Event following the presentation of the results from the ATOMIC-AHF trial at the European Society of Cardiology Congress 2013.
Toggle Summary Cytokinetics to Present at 32nd Annual Canaccord Global Growth Conference
South San Francisco, CA, August 9, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 32 nd Annual Canaccord Global Growth Conference on August 15, 2013 at 11:00 AM Eastern
Toggle Summary Cytokinetics, Incorporated Reports Second Quarter 2013 Financial Results
Company Provides Updated Financial and Milestone Guidance in Connection with Recent Strategic Transactions and Clinical Trials Progress SOUTH SAN FRANCISCO, CA, July 31, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and development revenues for the second quarter of 2013
Toggle Summary Cytokinetics Provides Additional Update and Revised Guidance For BENEFIT-ALS
Protocol Amended to Preserve the Intended Scientific Value of the Clinical Trial Patient Enrollment Expected to Conclude in 2013 and Results Expected in Early 2014 South San Francisco, CA, July 23, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today an amendment to the protocol for
Toggle Summary Cytokinetics to Announce Second Quarter Results on July 31, 2013
South San Francisco, CA., July 18, 2013, - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report second quarter results on Wednesday, July 31, 2013 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at
Toggle Summary Cytokinetics Provides Update on BENEFIT-ALS
South San Francisco, CA, July 8, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today an update on the conduct of BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS).  BENEFIT-ALS is a Phase IIb, multinational, double-blind,
Toggle Summary Cytokinetics and Astellas Announce Collaboration in the Field of Skeletal Muscle Activation
    Collaboration Will Focus on Expanding the New Frontier of Muscle Biology Cytokinetics is Eligible to Receive Over $40 Million During the Initial Two Years in Addition to Over $450 Million in Potential Milestone Payments plus Royalties South San Francisco, CA, and Tokyo, June 25 , 2013 -
Toggle Summary Cytokinetics Announces 1-for-6 Reverse Stock Split
South San Francisco, CA   June 24, 2013  -  Cytokinetics, Incorporated (NASDAQ:CYTK) announced today that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a one-for-six reverse stock split of its common stock, effective as of 5:00 p.m.
Toggle Summary Cytokinetics Announces Results From ATOMIC-AHF Will Be Presented At Late Breaking Clinical Trials Session At The European Society Of Cardiology Congress 2013
South San Francisco, CA   June 18, 2013  -  Cytokinetics Incorporated (NASDAQ:CYTK) announced today that results from ATOMIC-AHF have been accepted for presentation during a Hot Line Late Breaking Trials Session at the European Society of Cardiology (ESC) Congress 2013.
Toggle Summary Cytokinetics Set to Join Russell Global Index
South San Francisco, CA   June 17, 2013  -  Cytokinetics Incorporated (NASDAQ:CYTK) announced today that it is set to join the Russell Global Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 28, 2013, according to a preliminary list of
Toggle Summary Amgen and Cytokinetics Announce Expansion of License for Omecamtiv Mecarbil
Cytokinetics Will Receive $25 Million Plus Potential Milestone Payments and Royalties THOUSAND OAKS, Calif. AND SOUTH SAN FRANCISCO, Calif, (June 12, 2013) - Amgen (NASDAQ:AMGN) and Cytokinetics Incorporated (NASDAQ:CYTK) today announced an expansion of their strategic collaboration to include
Toggle Summary Cytokinetics Announces Publications Relating to Fast Skeletal Troponin Activation in Nemaline Myopathy
Translational Research Suggests a New Therapeutic Approach to Rare Muscle Disease South San Francisco, CA, June 4, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication of three peer-reviewed manuscripts co-authored by company scientists with a group led by Dr.
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
South San Francisco, CA., May 15, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that its Annual Meeting of Stockholders will be held on Tuesday, May 22, 2013 at 1:30 PM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San Francisco, CA.
Toggle Summary Cytokinetics, Incorporated Reports First Quarter 2013 Financial Results
Company Elaborates on Key Progress in Cardiac and Skeletal Muscle Programs SOUTH SAN FRANCISCO, CA, April 30, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and development revenues of $0.8 million for the first quarter of 2013.
Toggle Summary Cytokinetics to Announce First Quarter Results on April 30, 2013
South San Francisco, CA., April 16, 2013, - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report first quarter results on Tuesday, April 30, 2013 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at
Toggle Summary Cytokinetics Announces Grant From Families with Spinal Muscular Atrophy for Preclinical Development of Tirasemtiv
Award to Support Testing of Tirasemtiv   in Mouse Models of Spinal Muscular Atrophy South San Francisco, CA, and Elk Grove Village, IL, April 4, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) and Families of Spinal Muscular Atrophy (FSMA) announced the award of a grant from FSMA to
Toggle Summary Cytokinetics Announces Initiation of First-Time-in-Humans, Phase I Clinical Trial of CK-2127107
Second Drug Candidate from Cytokinetics' Fast Skeletal Muscle Activator Program Begins Clinical Trial in Expanded Development Program South San Francisco, CA, April 1, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the initiation of a first-time-in-humans, Phase I clinical trial
Toggle Summary Cytokinetics to Present at Upcoming Healthcare Conferences
South San Francisco, CA, March 29, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following healthcare conferences: Future Leaders in the Biotechnology Industry
Toggle Summary Cytokinetics Announces Presentation of Phase IIA Clinical Trial Data of Tirasemtiv in Patients with Myasthenia Gravis
Positive Results from Evidence of Effect Trial Inform Translation of Novel Mechanism of Action South San Francisco, CA, March 21, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced the presentation yesterday of positive data from a completed Phase IIa "Evidence of Effect" clinical trial of
Toggle Summary Cytokinetics Announces Update to Heart Failure Program
ATOMIC-AHF Has Completed Patient Enrollment; Dosing of Patients in COSMIC-HF Has Initiated   South San Francisco, CA, March 18, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that ATOMIC-AHF has completed patient enrollment in its third and final cohort.
Toggle Summary Cytokinetics to Present Clinical Trial Data Relating to Tirasemtiv in Patients with Myasthenia Gravis
Phase IIa data to be Presented at the 65 th Annual Meeting of the American Academy of Neurology   South San Francisco, CA, March 13, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that an Emerging Science Session poster presentation relating to tirasemtiv is scheduled to be
Toggle Summary Cytokinetics to Present at 25th Annual Roth Conference
South San Francisco, CA, March 11, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 25 th Annual Roth Conference on Monday, March 18, 2013 at 9:00 AM Pacific Time in Salon
Toggle Summary Cytokinetics to Present at Upcoming Healthcare Conferences
South San Francisco, CA, February 22, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that members of its management team are scheduled to participate at the following healthcare conferences:   Canaccord Genuity Orphan Drug One-on-One Day Date: Monday, February 25 th Location:
Toggle Summary Cytokinetics Announces Opening of COSMIC-HF, a Phase II Clinical Trial of Oral Formulations of Omecamtiv Mecarbil in Patients with Heart Failure
South San Francisco, CA, February 12, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the opening to enrollment of a Phase II clinical trial of oral formulations of omecamtiv mecarbil .  This trial, known as COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C
Toggle Summary Cytokinetics to Present at BIO CEO and Investor Conference
South San Francisco, CA., February 8, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the BIO CEO and Investor Conference on Monday, February 11, 2013 at 1:30 p.m.
Toggle Summary Cytokinetics Announces Changes to Its Board of Directors
Steve Dow Will Not Stand for Re-Election at the Annual Meeting of Shareholders; B. Lynne Parshall Has Been Appointed to the Company's Board South San Francisco, CA, February 8, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Steve Dow has provided notification that he will not
Toggle Summary Cytokinetics, Incorporated Reports Fourth Quarter 2012 Financial Results
Company Recaps Significant Milestones in Ongoing Phase IIb Clinical Trials Expected to Generate Results in 2013 SOUTH SAN FRANCISCO, CA, February 5, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and development revenues of $2.2 million for the fourth quarter of 2012.
Toggle Summary Cytokinetics to Announce Fourth Quarter Results on February 5, 2013
South San Francisco, CA., January 29, 2013, - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report fourth quarter results on Tuesday, February 5, 2013 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call
Toggle Summary Cytokinetics, Incorporated Receives NASDAQ Notice of Minimum Bid Price Compliance
South San Francisco, CA, January 25, 2013 - Cytokinetics, Incorporated (NASDAQ: CYTK), announced today that it has received a notice from The Nasdaq Stock Market ("Nasdaq") confirming that for the last 10 consecutive business days, the closing bid price of the Company's common stock has
Toggle Summary Cytokinetics, Incorporated Announces Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
South San Francisco, CA - December 18, 2012 - Cytokinetics, Incorporated (NASDAQ: CYTK), announced today that NASDAQ has approved the Company's request to voluntarily transfer the listing of its shares of common stock from The NASDAQ Global Market to The NASDAQ Capital Market.
Toggle Summary Cytokinetics Highlights Progress of Activities Directed to Muscle Biology at Today's Research & Development Day
  Two First-In-Class Programs Advancing in Phase IIb Clinical Trials   Company Convenes Panel of Experts to Discuss the Integrated Care of ALS Patients South San Francisco, CA, December 12, 2012 - Cytokinetics, Incorporated (Nasdaq: CYTK) is scheduled today to provide a corporate update
Toggle Summary Cytokinetics Announces Presentation of Additional Analyses from Clinical Trials of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis
Pharmacokinetics of Tirasemtiv Are Dose Proportional Positive and Concentration Dependent Effects Were Observed on Multiple Functional Measures South San Francisco, CA, December 7, 2012 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced a platform presentation of pharmacokinetic data and
Toggle Summary Cytokinetics to Present Clinical Trial Data Relating to Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis
Pharmacokinetics and Drug Interactions Analyses to be Presented at the 23rd International Symposium on ALS/MND South San Francisco, CA, November 29, 2012 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that a platform presentation relating to tirasemtiv is scheduled to be presented at
Toggle Summary Cytokinetics Announces Opening of Third and Final Cohort in ATOMIC-AHF
  Independent Data Monitoring Committee Recommends Progression in Ongoing Phase IIb Clinical Trial of Intravenous Form of Omecamtiv Mecarbil in Patients with Acute Heart Failure South San Francisco, CA, November 29, 2012 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the opening to
Toggle Summary Cytokinetics to Host Research and Development Day on Wednesday, December 12, 2012
Senior Management Will Provide Updates Relating to the Company's R&D Activities and Key Opinion Leaders Will Discuss the Potential Applications of Treatments Panel to Follow:  Integrated Support & Care of the ALS Patient South San Francisco, CA, November 28, 2012 - Cytokinetics,
Toggle Summary Cytokinetics to Present at the Lazard 9th Annual Healthcare Conference
South San Francisco, CA, November 7, 2012 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the Lazard 9 th Annual Healthcare Conference on Tuesday, November 13, 2012 at 8:00 AM Eastern Time at the
Toggle Summary Cytokinetics, Incorporated Reports Third Quarter 2012 Financial Results
Company Provides Updates Regarding Continued Progress in Phase IIb Clinical Development Programs in ALS and Heart Failure SOUTH SAN FRANCISCO, CA, October 30, 2012 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and development revenues of $1.7 million for the third quarter of
Toggle Summary Cytokinetics Announces Opening of BENEFIT-ALS, A Phase IIb Clinical Trial of Tirasemtiv (CK-2017357) in Patients with Amyotrophic Lateral Sclerosis
BENEFIT-ALS Will Evaluate Longer Term Effects of Novel Skeletal Muscle Activator and Represents a Key Step Forward Towards Potential Registration   South San Francisco, CA, October 29, 2012 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the company has opened BENEFIT-ALS ( B linded E
Toggle Summary Cytokinetics, Inc. : Cytokinetics to Announce Third Quarter Results on October 30, 2012
South San Francisco, CA., October 23, 2012, - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report third quarter results on Tuesday, October 30, 2012 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call
Toggle Summary Cytokinetics Announces Its Participation in the Launch of MyoKardia Through a Research Collaboration Directed to Hypertrophic Cardiomyopathies
South San Francisco, CA, September 24, 2012 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is participating in the launch of MyoKardia, Inc., a start-up company that is focused to genetic heart disease.  MyoKardia is being funded by Third Rock Ventures with a $38 million
Toggle Summary Cytokinetics Congratulates Its Founders, James A. Spudich, Ph.D. and Ronald D. Vale, Ph.D., on their Receipt of the 2012 Lasker Award for Basic Medical Research
Lasker Award Winners' Research into Molecular Motors Formed the Foundation of Company's Research and Development Activities South San Francisco, CA, September 11, 2012 - Cytokinetics, Incorporated (Nasdaq: CYTK) extends congratulations to Dr. James Spudich and Dr.
Toggle Summary Cytokinetics Prepares to Initiate Registration Program for Tirasemtiv (CK-2017357) in Amyotrophic Lateral Sclerosis Following Recent Regulatory Interactions
South San Francisco, CA, September 10, 2012 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced that, following interactions with regulatory authorities, the company is proceeding to initiate a Phase IIb, international, randomized, double-blind, placebo-controlled, clinical trial designed to
Toggle Summary Cytokinetics to Present at The Rodman & Renshaw Global Investment Conference
South San Francisco, CA, September 4, 2012 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 11, 2012 at 11:40 AM
Toggle Summary Cytokinetics, Incorporated Reports Second Quarter 2012 Financial Results
Jul 31, 2012 (Marketwire via COMTEX) --Cytokinetics, Incorporated ( NASDAQ : CYTK ) reported total research and development revenues of $1.8 million for the second quarter of 2012. The net loss allocable to common stockholders for the second quarter was $10.3 million, or $0.13 per basic and diluted
Toggle Summary Cytokinetics Announces Heart Failure Program Update
Jul 26, 2012 (Marketwire via COMTEX) --Cytokinetics, Incorporated ( NASDAQ : CYTK ) announced today that the company and Amgen have reviewed data arising from a recently completed Phase I clinical trial designed to assess the safety, tolerability and pharmacokinetics of modified release oral
Toggle Summary Cytokinetics to Announce Second Quarter Results on July 31, 2012
Jul 24, 2012 (Marketwire via COMTEX) -- Cytokinetics, Incorporated ( NASDAQ : CYTK ) announced today that it is scheduled to report second quarter results on Tuesday, July 31, 2012 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at
Toggle Summary Cytokinetics to Present at 7th Annual JMP Securities Healthcare Conference
SOUTH SAN FRANCISCO, CA, Jul 05, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 7th Annual JMP Securities Healthcare Conference on Thursday, July 12, 2012 at 9:30
Toggle Summary Cytokinetics, Incorporated Announces $60 Million Financing
SOUTH SAN FRANCISCO, CA, Jun 20, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the pricing of concurrent, separate underwritten offerings of (i) 55.9M shares of its common stock and accompanying warrants to purchase 0.6 shares of common stock for each
Toggle Summary Cytokinetics Announces Proposed Public Offerings of Common Stock and Warrants and Series B Convertible Preferred Stock and Warrants
SOUTH SAN FRANCISCO, CA, Jun 19, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is concurrently offering to sell, subject to market and other conditions, (i) shares of its common stock and corresponding warrants to purchase 0.60 of a share of common
Toggle Summary Cytokinetics, Incorporated Receives NASDAQ Notice of Minimum Bid Price Non-Compliance
SOUTH SAN FRANCISCO, CA, Jun 19, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK), announced today that it has received a letter from the listing qualifications department staff of The NASDAQ Stock Market LLC, notifying Cytokinetics that for the last 30 consecutive business
Toggle Summary Cytokinetics Announces Publication of Phase II Evidence of Effect Study of CK-2017357 in the Journal Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, CA, Jun 12, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the publication of its Phase II Evidence of Effect (EoE) clinical study of CK-2017357, an orally bioavailable fast skeletal muscle troponin activator, in patients with
Toggle Summary Cytokinetics Announces Opening of Second Cohort in Phase IIb Clinical Trial of Intravenous Omecamtiv Mecarbil in Patients With Acute Heart Failure
Independent Data Monitoring Committee Recommends Progression to Second Cohort SOUTH SAN FRANCISCO, CA, May 24, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the opening to enrollment of the second cohort in the ongoing, international, randomized,
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, CA, May 15, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that its Annual Meeting of Stockholders will be held on Tuesday, May 22, 2012 at 10:00 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San
Toggle Summary Cytokinetics Announces Company Participation and Support of ALS Fundraising Activities in Connection With ALS Awareness Month
SOUTH SAN FRANCISCO, CA, May 09, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that, in connection with Amyotrophic Lateral Sclerosis (ALS) Awareness Month, the company has committed to several educational and support activities for ALS patients and their
Toggle Summary Cytokinetics, Incorporated Reports First Quarter 2012 Financial Results
Company Reviews Recent Advancements in Its Skeletal and Cardiac Muscle Contractility Programs SOUTH SAN FRANCISCO, CA, Apr 26, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) reported total research and development revenues of $1.8 million for the first quarter of 2012.
Toggle Summary Cytokinetics Announces Presentation of Preclinical Data Regarding CK-2017357 at the 2012 Experimental Biology Annual Conference
Presentation Highlights Improvement in Resistance to Muscle Fatigue SOUTH SAN FRANCISCO, CA, Apr 26, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that preclinical data regarding CK-2017357 were presented in a poster presentation at the 2012 Experimental
Toggle Summary Cytokinetics Announces Encouraging Results From Two Phase II Clinical Trials Evaluating CK-2017357 in Patients With Amyotrophic Lateral Sclerosis
Safety and Tolerability of CK-2017357 in These Two Trials Support Progression to Registration Stage Program SOUTH SAN FRANCISCO, CA, Apr 25, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today encouraging results from two Phase II clinical trials evaluating
Toggle Summary Cytokinetics to Announce First Quarter Results on April 26, 2012
SOUTH SAN FRANCISCO, CA, Apr 19, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report first quarter results on Thursday, April 26, 2012 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a
Toggle Summary Cytokinetics Announces CK-2017357 Receives Fast Track Designation From the FDA for the Potential Treatment of Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, CA, Apr 19, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that CK-2017357, its fast skeletal muscle troponin activator, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of
Toggle Summary Cytokinetics Announces Clinical Trial Data Relating to CK-2017357 to Be Presented at the 64th Annual Meeting of the American Academy of Neurology
Additional Preclinical Trial Data to Be Presented at the 2012 Experimental Biology Conference SOUTH SAN FRANCISCO, CA, Apr 18, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that one oral presentation and two poster presentations are scheduled to be
Toggle Summary Cytokinetics to Present at the Eleventh Annual Needham Life Sciences Conference
SOUTH SAN FRANCISCO, CA, Mar 27, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the Eleventh Annual Needham Life Sciences Conference on Tuesday, April 3, 2012 at 2:00 PM
Toggle Summary Cytokinetics Announces Changes to Its Board of Directors
Resignation of Jim Spudich and Election of Sandy Smith SOUTH SAN FRANCISCO, CA, Mar 07, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the resignation of James A. Spudich, Ph.D. from the company's Board of Directors. Dr.
Toggle Summary Cytokinetics Announces That the European Medicines Agency Has Granted CK-2017357 Orphan Medicinal Product Designation for the Treatment of Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, CA, Mar 06, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the European Medicines Agency (EMA) has granted the company's fast skeletal muscle troponin activator CK-2017357 orphan medicinal product designation for the treatment of
Toggle Summary Cytokinetics Announces Fundamental Research in the Field of Fast Skeletal Muscle Activation Published in the Journal Nature Medicine
Novel Mechanistic Approach to Directly Modulating Muscle Contractility May Represent a Promising Strategy to Treat Serious Neuromuscular Disorders SOUTH SAN FRANCISCO, CA, Mar 05, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the publication of preclinical
Toggle Summary Cytokinetics to Present at March Healthcare Conferences
SOUTH SAN FRANCISCO, CA, Feb 28, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the following healthcare conferences during the month of March: Cowen & Company 32nd
Toggle Summary Cytokinetics Announces Initiation of Phase I Clinical Trial of Oral Formulations of Omecamtiv Mecarbil in Healthy Volunteers
SOUTH SAN FRANCISCO, CA, Feb 21, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the initiation of a Phase I study designed to assess the safety, tolerability and pharmacokinetics of multiple oral formulations of omecamtiv mecarbil in healthy volunteers.
Toggle Summary Cytokinetics to Present at BIO CEO and Investor Conference
SOUTH SAN FRANCISCO, CA, Feb 06, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the BIO CEO and Investor Conference on Monday, February 13, 2012 at
Toggle Summary Cytokinetics, Incorporated Reports Fourth Quarter and Year End Highlights and 2011 Financial Results
Company Provides Financial Guidance and Expected Milestones for 2012; Ongoing Phase II Trials of Omecamtiv Mecarbil and CK-2017357 Inform Next Steps in Clinical Development Programs SOUTH SAN FRANCISCO, CA, Feb 02, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) reported
Toggle Summary Cytokinetics to Announce Fourth Quarter and Year End Results on February 2, 2012
SOUTH SAN FRANCISCO, CA, Jan 26, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report fourth quarter and year end results on Thursday, February 2, 2012 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior
Toggle Summary Cytokinetics Announces Positive Results From Phase II Clinical Trial Evaluating CK-2017357 in Patients With Amyotrophic Lateral Sclerosis
CK-2017357 Demonstrated to Be Well-Tolerated in First Cohort of Ongoing Clinical Trial SOUTH SAN FRANCISCO, CA, Nov 30, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today positive results from the first cohort, or Part A, of a continuing Phase II clinical
Toggle Summary Cytokinetics Announces Opening of Third Phase II Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis
Clinical Trial Will Evaluate Safety and Tolerability of Ascending Doses of CK-2017357 SOUTH SAN FRANCISCO, CA, Nov 29, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened enrollment in a third Phase II clinical trial of CK-2017357 in
Toggle Summary Cytokinetics Files Replacement Shelf Registration Statement
SOUTH SAN FRANCISCO, CA, Nov 25, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it has filed a shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission (SEC). The shelf registration statement, if declared effective by
Toggle Summary Cytokinetics to Present Clinical Trial Data Relating to CK-2017357 in Patients With Amyotrophic Lateral Sclerosis
Results to Be Presented at the 22nd International Symposium on ALS/MND SOUTH SAN FRANCISCO, CA, Nov 22, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two posters are scheduled to be presented at the 22nd International Symposium on ALS/MND to be held
Toggle Summary Cytokinetics to Present at Eighth Annual Lazard Capital Markets Healthcare Conference
SOUTH SAN FRANCISCO, CA, Nov 08, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the Eighth Annual Lazard Capital Markets Healthcare Conference on Tuesday, November 15,
Toggle Summary Cytokinetics Announces Initiation of Second Cohort of Ongoing Phase II Clinical Trial Evaluating CK-2017357 in Patients With ALS
SOUTH SAN FRANCISCO, CA, Nov 01, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the initiation of a second cohort, or Part B, of an ongoing Phase II clinical trial of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS).
Toggle Summary Cytokinetics, Incorporated Reports Third Quarter 2011 Financial Results
Company Updates Clinical Trials and Regulatory Plans Related to the Development of CK-2017357 in ALS Patients; Reductions in Spending Enable Prioritization and Advancement of Skeletal Muscle Activator Program SOUTH SAN FRANCISCO, CA, Oct 27, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics,
Toggle Summary Cytokinetics to Announce Third Quarter Results on October 27, 2011
SOUTH SAN FRANCISCO, CA, Oct 20, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report third quarter results on Thursday, October 27, 2011 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior management will
Toggle Summary Cytokinetics Announces Strategic Restructuring
Company Aligns Resources to Focus on the Late-Stage Development of CK-2017357 in ALS and Omecamtiv Mecarbil in Heart Failure SOUTH SAN FRANCISCO, CA, Oct 18, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced plans today to restructure the company's workforce and
Toggle Summary Cytokinetics Announces First Publication on Smooth Muscle Myosin Inhibitors in The Journal of Pharmacology and Experimental Therapeutics
Findings Demonstrate the Potential Therapeutic Application of Inhibitors of Smooth Muscle Myosin for the Treatment of Hypertension SOUTH SAN FRANCISCO, CA, Sep 27, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced the publication of preclinical research relating to
Toggle Summary Cytokinetics to Present at September Healthcare Conferences
SOUTH SAN FRANCISCO, CA, Sep 06, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the following healthcare conferences during the month of September: Rodman & Renshaw
Toggle Summary Cytokinetics Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet
Results From These Trials Form the Basis for Ongoing Phase IIb Activities in Collaboration With Amgen SOUTH SAN FRANCISCO, CA, Aug 19, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the publication of results from two clinical trials of omecamtiv mecarbil,
Toggle Summary Cytokinetics to Present at 31st Annual Canaccord Genuity Growth Conference
SOUTH SAN FRANCISCO, CA, Aug 04, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 31st Annual Canaccord Genuity Growth Conference on Thursday, August 11, 2011 at 10:00
Toggle Summary Cytokinetics, Incorporated Reports Second Quarter 2011 Financial Results
SOUTH SAN FRANCISCO, CA, Jul 28, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) reported total research and development revenues of $1.1 million for the second quarter of 2011. The net loss allocable to common stockholders for the second quarter was $16.5 million, or
Toggle Summary Cytokinetics to Announce Second Quarter Results on July 28, 2011
SOUTH SAN FRANCISCO, CA, Jul 21, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report second quarter results on Thursday, July 28, 2011 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior management will
Toggle Summary Cytokinetics Announces Opening of Next Phase II Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis
Company Provides Update on Plans for CK-2017357 and Other Next Generation Skeletal Muscle Activators SOUTH SAN FRANCISCO, CA, Jun 21, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened enrollment in a second Phase II clinical trial
Toggle Summary Cytokinetics Announces Successful Completion of Phase IIA "Evidence of Effect" Clinical Trial of CK-2017357, in Patients With Claudication Associated With Peripheral Artery Disease
Clinical Trial Demonstrates Translation of Mechanism of Action of Novel Drug Candidate in 2nd Disease Population SOUTH SAN FRANCISCO, CA, Jun 02, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced the successful completion of its Phase IIa "Evidence of Effect"
Toggle Summary Cytokinetics to Present Clinical Data Relating to CK-2017357 at the 22nd Annual Sessions of the Society for Vascular Medicine
SOUTH SAN FRANCISCO, CA, May 26, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two posters relating to CK-2017357 are scheduled to be presented at the 22nd Annual Sessions of the Society for Vascular Medicine to be held June 2-4, 2011 at the Seaport
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, CA, May 11, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that its Annual Meeting of Stockholders will be held on Wednesday, May 18, 2011 at 10:00 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South
Toggle Summary Cytokinetics, Incorporated Reports First Quarter 2011 Financial Results
Company Reviews Advancements in the Cardiac Muscle Contractility Program and Outlines Plans Relating to the Skeletal Muscle Contractility Program SOUTH SAN FRANCISCO, CA, Apr 27, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) reported total research and development
Toggle Summary Cytokinetics to Present at May Healthcare Conferences
SOUTH SAN FRANCISCO, CA, Apr 25, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the following healthcare conferences during the month of May: Deutsche Bank 36th Annual
Toggle Summary Cytokinetics to Announce First Quarter Results on April 27, 2011
SOUTH SAN FRANCISCO, CA, Apr 20, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report first quarter results on Wednesday, April 27, 2011 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior management will
Toggle Summary Cytokinetics Announces Opening of Phase IIb Clinical Trial of Intravenous Formulation of Omecamtiv Mecarbil in Patients With Acute Heart Failure
SOUTH SAN FRANCISCO, CA, Apr 19, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the opening to enrollment of a Phase IIb clinical trial of an intravenous formulation of omecamtiv mecarbil. This trial is being conducted by Amgen in collaboration with
Toggle Summary Cytokinetics, Incorporated Announces $20 Million Financing
SOUTH SAN FRANCISCO, CA, Apr 18, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) today announced that it has entered into a definitive agreement to sell 5.3 million shares of its Common Stock at a price of $1.50 per share, and 8,070 shares of its Series A Convertible
Toggle Summary Cytokinetics Announces Presentation of Data From a Phase IIa Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis at the 63rd Annual Meeting of the American Academy of Neurology
Presentation Included Additional Results Arising From Recent Analyses Relating to Muscle Strength at 24 Hours and Concentration-Response Relationships SOUTH SAN FRANCISCO, CA, Apr 18, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced that clinical data from its
Toggle Summary Cytokinetics Announces Data From Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis to Be Presented at the 63rd Annual Meeting of the American Academy of Neurology
SOUTH SAN FRANCISCO, CA, Apr 11, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an oral presentation of results from its Phase IIa "Evidence of Effect" (EoE) clinical trial of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS) is
Toggle Summary Cytokinetics to Present at Tenth Annual Needham Life Sciences Conference
SOUTH SAN FRANCISCO, CA, Mar 29, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the Tenth Annual Needham Life Sciences Conference on Tuesday, April 5, 2011 at 10:00 AM
Toggle Summary Cytokinetics Announces Fundamental Research in the Field of Cardiac Myosin Activation Published in the Journal Science
Novel Mechanistic Approach to Directly Modulating Muscle Contractility May Represent a Promising Strategy to Treat Systolic Heart Failure SOUTH SAN FRANCISCO, CA, Mar 18, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the publication of preclinical
Toggle Summary Cytokinetics to Present at March Healthcare Conferences
SOUTH SAN FRANCISCO, CA, Feb 22, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the following healthcare conferences during the month of March: 2011 Citi Global
Toggle Summary Cytokinetics, Incorporated Reports Fourth Quarter and Year End Highlights and 2010 Financial Results
Company Outlines Next Steps in Phase II Clinical Development Programs of Omecamtiv Mecarbil in Heart Failure and CK-2017357 in ALS SOUTH SAN FRANCISCO, CA, Feb 14, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) reported total research and development revenues of $1.1
Toggle Summary Cytokinetics Announces Changes to Its Board of Directors
Resignation of Grant Heidrich and Election of Wendell Wierenga SOUTH SAN FRANCISCO, CA, Feb 10, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the resignation of A. Grant Heidrich III from the company's Board of Directors. Mr.
Toggle Summary Cytokinetics Provides Update Regarding Omecamtiv Mecarbil Clinical Development Program
Initiation of a Phase IIb Clinical Trial Expected in the First Half of 2011 SOUTH SAN FRANCISCO, CA, Feb 09, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that, in the first half of 2011, the company and its partner, Amgen Inc., plan to initiate a Phase
Toggle Summary Cytokinetics to Announce Fourth Quarter and Year End 2010 Results on February 14, 2011
SOUTH SAN FRANCISCO, CA, Feb 07, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report fourth quarter and year end 2010 results on Monday, February 14, 2011 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior
Toggle Summary Cytokinetics to Present at BIO CEO and Investor Conference
SOUTH SAN FRANCISCO, CA, Feb 04, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the BIO CEO and Investor Conference on Monday, February 14, 2011 at
Toggle Summary Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 in Patients With Myasthenia Gravis
SOUTH SAN FRANCISCO, CA, Jan 04, 2011 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened enrollment in a Phase IIa "Evidence of Effect" (EoE) clinical trial of CK-2017357 in patients with generalized myasthenia gravis (MG).
Toggle Summary Cytokinetics to Present at the Deutsche Bank BIOFest Conference
SOUTH SAN FRANCISCO, CA, Dec 14, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Deutsche Bank BIOFest Conference on Tuesday, December 14th at 3:00
Toggle Summary Cytokinetics Announces Successful Completion of Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis
Treatment With Novel Skeletal Muscle Troponin Activator Results in Improvements in Patients' and Investigators' Global Assessments of Change in a Dose Dependent Fashion; Data Demonstrate Increases in Multiple Clinically Relevant Pharmacodynamic Assessments; Cytokinetics to Host Investor Event and
Toggle Summary Cytokinetics to Host Investor Event on December 13, 2010
Panel to Discuss the Results of the Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis SOUTH SAN FRANCISCO, CA, Dec 09, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company is scheduled to
Toggle Summary Cytokinetics Announces Presentation of Phase IIa "Evidence of Effect" Clinical Trial Data Relating to CK-2017357 in Patients With Amyotrophic Lateral Sclerosis
Results to Be Presented in the Clinical Trials Session at the 21st International Symposium on ALS/MND SOUTH SAN FRANCISCO, CA, Dec 07, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an oral presentation of results from its Phase IIa "Evidence of
Toggle Summary Cytokinetics to Present at Canaccord Genuity 5th Annual Cardiovascular, Diabetes and Obesity Conference
SOUTH SAN FRANCISCO, CA, Nov 30, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at Canaccord Genuity's 5th Annual Cardiovascular, Diabetes and Obesity Conference on
Toggle Summary Cytokinetics to Present at November Healthcare Conferences
SOUTH SAN FRANCISCO, CA, Nov 03, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company is scheduled to present at the following healthcare conferences during the month of November: Presenter: Robert I.
Toggle Summary Cytokinetics Announces Changes to Its Board of Directors
Resignation of Michael Schmertzler and Election of Santo J. Costa SOUTH SAN FRANCISCO, CA, Nov 01, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the resignation of Michael Schmertzler from the company's Board of Directors. Mr.
Toggle Summary Cytokinetics, Incorporated Reports Third Quarter 2010 Financial Results
Company Reports Encouraging Results From Interim Reviews of Two Ongoing Phase IIa Evidence of Effect Trials of CK-2017357 SOUTH SAN FRANCISCO, CA, Oct 28, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) reported revenues from research and development collaborations of $0.4
Toggle Summary Cytokinetics Announces the Selection of CK-2017357 to Windhover's "Top 10 HOT SPACE Projects to Watch" List
Industry Experts Recognize Partnering Prospects of Novel Skeletal Muscle Activator SOUTH SAN FRANCISCO, CA, Oct 27, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that CK-2017357, its novel fast skeletal muscle troponin activator, has been named one of
Toggle Summary Cytokinetics to Announce Third Quarter Results on October 28, 2010
SOUTH SAN FRANCISCO, CA, Oct 21, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report third quarter results on Thursday, October 28, 2010 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior management will
Toggle Summary Cytokinetics Announces Presentation of Clinical and Non-Clinical Data Relating to CK-2017357 at the 2010 Annual Aging Muscle Symposium
Results Provide Supportive Evidence for Ongoing Phase IIa Evidence of Effect Clinical Trials SOUTH SAN FRANCISCO, CA, Oct 01, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two abstracts relating to CK-2017357 were presented at the 2010 Annual Aging
Toggle Summary Cytokinetics to Present Clinical and Non-Clinical Data Relating to CK-2017357 at the 2010 Annual Aging Muscle Symposium
SOUTH SAN FRANCISCO, CA, Sep 28, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two abstracts relating to CK-2017357 are scheduled for presentation at the 2010 Annual Aging Muscle Symposium to be held September 30 - October 1, 2010 in the Sakura Room
Toggle Summary Cytokinetics Provides Update Regarding Omecamtiv Mecarbil Clinical Development Program
Initiation of a Phase IIb Clinical Trial of Intravenous Formulation Planned to Occur Prior to Clinical Trials of Oral Formulations SOUTH SAN FRANCISCO, CA, Sep 21, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company and its partner, Amgen Inc.,
Toggle Summary Cytokinetics to Present at the JMP Securities Healthcare Conference
SOUTH SAN FRANCISCO, CA, Sep 20, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Fifth Annual JMP Securities Healthcare Conference on Monday,
Toggle Summary Phase I Clinical Trial Data Relating to Omecamtiv Mecarbil Presented at the 2010 Heart Failure Society of America Annual Meeting
Investigators Conclude That Omecamtiv Mecarbil Improved Left Atrial Performance in Healthy Volunteers SOUTH SAN FRANCISCO, CA, Sep 14, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that additional Phase I clinical trial data relating to omecamtiv mecarbil
Toggle Summary Additional Phase I Clinical Trial Data Related to Omecamtiv Mecarbil to Be Presented at the 2010 Heart Failure Society of America Annual Meeting
SOUTH SAN FRANCISCO, CA, Sep 08, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that additional Phase I clinical trial data relating to omecamtiv mecarbil (formerly CK-1827452) is scheduled to be presented as a poster presentation at the 2010 Heart Failure
Toggle Summary Cytokinetics to Present at Canaccord Genuity Global Growth Conference
SOUTH SAN FRANCISCO, CA, Aug 04, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Canaccord Genuity 30th Annual Global Growth Conference 2010 on
Toggle Summary Cytokinetics, Incorporated Reports Second Quarter 2010 Financial Results
Company Reports on Progress of Drug Candidates in Clinical Trials; Interim Review of Data From Phase IIa Evidence of Effect Trial in ALS Patients Supports Continuation SOUTH SAN FRANCISCO, CA, Jul 28, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) reported revenues from
Toggle Summary Cytokinetics Announces Award of Grant for Preclinical and Clinical Development of CK-2017357 in Myasthenia Gravis
SOUTH SAN FRANCISCO, CA, Jul 26, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the National Institute of Neurological Disorders and Stroke (NINDS) has awarded the company a grant in the amount of $2.9 million to support research and development of
Toggle Summary Cytokinetics Announces Presentation of Phase I Data Relating to CK-2017357 at the XII International Congress on Neuromuscular Diseases
Results Demonstrate that Novel Mechanism of Company's Fast Skeletal Muscle Troponin Activator Translates to Potentially Clinically Relevant Effects on Muscle Performance in Humans SOUTH SAN FRANCISCO, CA, Jul 22, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced
Toggle Summary Cytokinetics to Announce Second Quarter Results on July 28, 2010
SOUTH SAN FRANCISCO, CA, Jul 21, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report second quarter results on Wednesday, July 28, 2010 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior management will
Toggle Summary Cytokinetics to Present Phase I Data Relating to CK-2017357 at the XII International Congress on Neuromuscular Diseases
SOUTH SAN FRANCISCO, CA, Jul 14, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a poster summarizing Phase I data relating to CK-2017357 is scheduled to be presented in the Late Breaking News Poster Presentation Session at the XII International
Toggle Summary Cytokinetics to Present at June Healthcare Conferences
SOUTH SAN FRANCISCO, CA, Jun 01, 2010 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company is scheduled to present at the following healthcare conferences during the month of June: Jefferies 2010 Global Life Sciences Conference Date: Tuesday, June 8,
Toggle Summary Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 in Patients With Peripheral Artery Disease and Claudication
SOUTH SAN FRANCISCO, CA, May 27, 2010 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened to enrollment a Phase IIa "Evidence of Effect" (EoE) clinical trial of CK-2017357 in patients with peripheral artery disease and claudication.
Toggle Summary Cytokinetics Announces Presentation of Non-Clinical Data From Its Smooth Muscle Contractility Program at the American Thoracic Society's 2010 International Conference
Inhibitors of Smooth Muscle Myosin May Offer a Novel Therapeutic Approach to the Treatment of Chronic Obstructive Pulmonary Disease and Asthma SOUTH SAN FRANCISCO, CA, May 18, 2010 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a poster summarizing
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, CA, May 13, 2010 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that its Annual Meeting of Stockholders will be held on Thursday, May 20, 2010 at 10:00 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South
Toggle Summary Cytokinetics to Present Non-Clinical Data From Its Smooth Muscle Contractility Program at the American Thoracic Society's 2010 International Conference
SOUTH SAN FRANCISCO, CA, May 11, 2010 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing non-clinical data regarding its smooth muscle contractility program is scheduled to be presented at the American Thoracic Society's 2010
Toggle Summary Cytokinetics, Incorporated Reports First Quarter 2010 Financial Results
Advancement of CK-2017357 Into Phase IIa Evidence of Effect Studies; Planning Underway for a Phase IIb Clinical Trial of Intravenous Formulation of Omecamtiv Mecarbil With Initiation Anticipated in 2010 SOUTH SAN FRANCISCO, CA, Apr 29, 2010 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated
Toggle Summary Cytokinetics Announces Presentation of Non-Clinical Data Relating to CK-2017357 at the Society for Vascular Medicine's 2010 Annual Meeting
Results Support Initiation of Phase IIa Evidence of Effect Clinical Trial Evaluating CK-2017357 in Patients with Claudication SOUTH SAN FRANCISCO, CA, Apr 28, 2010 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a poster summarizing non-clinical data
Toggle Summary Cytokinetics to Present at May Healthcare Conferences
SOUTH SAN FRANCISCO, CA, Apr 27, 2010 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that members of its executive team are scheduled to present at the following three upcoming healthcare conferences throughout the month of May: Deutsche Bank's 35th Annual
Toggle Summary Cytokinetics to Announce First Quarter Results on April 29, 2010
SOUTH SAN FRANCISCO, CA, Apr 22, 2010 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report first quarter results on Thursday, April 29, 2010 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior management will host
Toggle Summary Cytokinetics to Present Non-Clinical Data Relating to CK-2017357 at the Society for Vascular Medicine's 2010 Annual Meeting
SOUTH SAN FRANCISCO, CA, Apr 21, 2010 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a poster summarizing non-clinical data regarding CK-2017357 is scheduled to be presented at the Society for Vascular Medicine's 2010 Annual Meeting: 21st Annual Scientific
Toggle Summary Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 for Patients With Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, CA, Mar 19, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened a Phase IIa "Evidence of Effect" (EoE) clinical trial of CK-2017357 for patients with amyotrophic lateral sclerosis (ALS), also known as Lou
Toggle Summary Cytokinetics Announces Changes to Its Board of Directors
SOUTH SAN FRANCISCO, CA, Mar 16, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced the resignation of James H. Sabry, M.D., Ph.D., Co-founder and former Chief Executive Officer, from the company's Board of Directors. Dr.
Toggle Summary Cytokinetics Announces Orphan Drug Designation Granted to CK-2017357 for the Treatment of Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, CA, Mar 10, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that its fast skeletal muscle troponin activator, CK-2017357, has been granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the potential
Toggle Summary Cytokinetics Announces Non-Clinical Data From Multiple Programs Presented at the Biophysical Society 54th Annual Meeting
<b>Results Arising From Skeletal and Smooth Muscle Contractility Research Underscore Company's Leadership Position in Programs Directed to Muscle Function</b> SOUTH SAN FRANCISCO, CA, Feb 23, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that
Toggle Summary Cytokinetics Announces Non-Clinical Data From Multiple Programs to Be Presented at the Biophysical Society 54th Annual Meeting
SOUTH SAN FRANCISCO, CA, Feb 12, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that five abstracts regarding its research programs are scheduled to be presented as poster presentations at the Biophysical Society 54th Annual Meeting to be held February
Toggle Summary Cytokinetics, Incorporated Reports Fourth Quarter and Year End 2009 Financial Results
Company Updates Progress on Programs and Provides Milestones and Financial Guidance for 2010 SOUTH SAN FRANCISCO, CA, Feb 03, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) reported revenues from research and development collaborations of $1.0 million for the fourth
Toggle Summary Cytokinetics to Present at BIO CEO and Investor Conference
SOUTH SAN FRANCISCO, CA, Feb 01, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the BIO CEO and Investor Conference on Monday, February 8th at 1:00
Toggle Summary Cytokinetics to Announce Fourth Quarter and Year End Results On February 3, 2010
SOUTH SAN FRANCISCO, CA, Jan 27, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report fourth quarter and year end results on Wednesday, February 3, 2010 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior
Toggle Summary Cytokinetics Announces Data From Phase I Multiple Dose Clinical Trial of CK-2017357
Results From Phase I Clinical Trials Program Support Movement Into Phase II SOUTH SAN FRANCISCO, CA, Jan 27, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced results from its Phase I, randomized, double-blind, placebo-controlled, multiple-dose clinical trial of
Toggle Summary Cytokinetics Announces Positive Data From Phase I Clinical Trial of CK-2017357
Statistically Significant Increases in Muscle Force Production Demonstrated During Treatment With Novel Skeletal Muscle Activator SOUTH SAN FRANCISCO, CA, Jan 11, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced positive data from Part B of its Phase I,
Toggle Summary Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 Presented at the 32nd Annual San Antonio Breast Cancer Symposium
SOUTH SAN FRANCISCO, CA, Dec 11, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing non-clinical data relating to GSK-923295, an inhibitor of centromere-associated protein E (CENP-E), was presented as a poster at the 32nd Annual
Toggle Summary Cytokinetics and GlaxoSmithKline Agree to Terminate Collaboration and License Agreement Directed to Oncology
Decision Consistent With Cytokinetics' Corporate Strategy to Focus Research and Development on Muscle Biology SOUTH SAN FRANCISCO, CA, Dec 09, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced that it has agreed with GlaxoSmithKline (GSK) to terminate their
Toggle Summary Cytokinetics Presents Non-Clinical Data Relating to CK-2017357 at the 5th Cachexia Conference
Results Support Therapeutic Hypotheses for Novel Mechanism Skeletal Muscle Activator Now Advancing Towards Phase II Clinical Trials SOUTH SAN FRANCISCO, CA, Dec 07, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that both a poster and an oral presentation
Toggle Summary Cytokinetics Announces Clinical Trial Data Regarding SB-743921 Presented at the 2009 American Society of Hematology Annual Meeting and Exposition
SOUTH SAN FRANCISCO, CA, Dec 06, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a poster summarizing clinical trial data regarding SB-743921 was presented at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition held December
Toggle Summary Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to Be Presented at the 32nd Annual San Antonio Breast Cancer Symposium
SOUTH SAN FRANCISCO, CA, Dec 03, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing non-clinical data relating to GSK-923295, an inhibitor of centromere-associated protein E (CENP-E), is scheduled to be presented as a poster
Toggle Summary Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2009 American Society of Hematology Annual Meeting and Exposition
SOUTH SAN FRANCISCO, CA, Nov 30, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing clinical trial data regarding SB-743921 is scheduled to be presented as a poster presentation at the 2009 American Society of Hematology (ASH)
Toggle Summary Cytokinetics to Present Non-Clinical Data Relating to CK-2017357 at the 5th Cachexia Conference
SOUTH SAN FRANCISCO, CA, Nov 30, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a poster and oral presentation summarizing non-clinical data regarding CK-2017357, a fast skeletal troponin activator, are scheduled to be presented at the 5th Cachexia
Toggle Summary Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 Presented at the 2009 AACR-NCI-EORTC International Conference
Data Support Hypothesis That GSK-923295 May Be Active in Combination With Other Chemotherapeutics in the Clinical Setting SOUTH SAN FRANCISCO, CA, Nov 19, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that abstracts summarizing non-clinical data relating
Toggle Summary Cytokinetics Presents Non-Clinical Data From Its Smooth Muscle Contractility Program at the 2009 Scientific Sessions of the American Heart Association
Data Supports Hypothesis That Inhibition of Smooth Muscle Myosin May Represent a Novel Approach to Treat Patients With Systemic or Pulmonary Hypertension SOUTH SAN FRANCISCO, CA, Nov 17, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three abstracts
Toggle Summary Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to Be Presented at the 2009 AACR-NCI-EORTC International Conference
SOUTH SAN FRANCISCO, CA, Nov 12, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that abstracts summarizing non-clinical data relating to GSK-923295, an inhibitor of centromere-associated protein E (CENP-E), are scheduled to be presented at the
Toggle Summary Cytokinetics to Present Non-Clinical Data From Its Smooth Muscle Contractility Program at the 2009 Scientific Sessions of the American Heart Association
SOUTH SAN FRANCISCO, CA, Nov 10, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three abstracts summarizing non-clinical data regarding its smooth muscle contractility program are scheduled to be presented at the 2009 Scientific Sessions of the
Toggle Summary Cytokinetics Announces Advancement of CK-2017357 in Phase I Clinical Trials
Company Initiates Additional Multi-Dose Trial and 2nd Stage of Ongoing Single-Dose Trial of Novel Skeletal Muscle Activator SOUTH SAN FRANCISCO, CA, Nov 09, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the initiation of a double-blind, randomized,
Toggle Summary Cytokinetics Announces Addition to Board of Directors
Company Announces Appointment of L. Patrick Gage, Ph.D. SOUTH SAN FRANCISCO, CA, Nov 06, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Pat Gage has been appointed to the company's Board of Directors. Dr.
Toggle Summary Cytokinetics to Present at November Healthcare Conferences
SOUTH SAN FRANCISCO, CA, Nov 03, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that members of its Executive team are scheduled to present at the following four upcoming healthcare conferences throughout the month of November: Merriman Curhan Ford's 6th
Toggle Summary Cytokinetics, Incorporated Reports Third Quarter 2009 Financial Results
Quarterly Highlights Include Company's Research and Development Day Elaborating on Expansion of Development Pipeline; Company Provides Update on Next Steps in Development of Omecamtiv Mecarbil SOUTH SAN FRANCISCO, CA, Oct 28, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK)
Toggle Summary Cytokinetics to Announce Third Quarter Results on October 28, 2009
SOUTH SAN FRANCISCO, CA, Oct 21, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report third quarter results on Wednesday, October 28, 2009 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior management will
Toggle Summary Cytokinetics to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
SOUTH SAN FRANCISCO, CA, Sep 29, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 4th Annual JMP Securities Healthcare Focus Conference on Tuesday,
Toggle Summary Cytokinetics Highlights Progress and Expansion of Development Programs at Today's Research and Development Day
Company Presents Data Supporting Advancement of First-in-Class Cardiac and Skeletal Muscle Activators in Clinical Trials; Pipeline of Novel Compounds in Clinical and Preclinical Development May Have Potential in Array of Therapeutic Applications SOUTH SAN FRANCISCO, CA, Sep 18, 2009 (MARKETWIRE via
Toggle Summary Cytokinetics Presents Phase IIa Clinical Trials Data on Omecamtiv Mecarbil at the 2009 Heart Failure Society of America Annual Meeting
Data From Phase IIa Trials Shared at Largest Gathering of U.S. Heart Failure Specialists; Safety and Pharmacodynamic Results Support Progression Into Further Clinical Trials SOUTH SAN FRANCISCO, CA, Sep 15, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today
Toggle Summary Cytokinetics to Host a Research and Development Day on Friday, September 18th
Senior Management Will Discuss the Company's Innovative R&D Activities and Review Its Novel Pipeline; Key Opinion Leaders Will Discuss the Potential Applications of Treatment SOUTH SAN FRANCISCO, CA, Sep 11, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today
Toggle Summary Cytokinetics to Present at the NewsMakers in the Biotech Industry Conference
SOUTH SAN FRANCISCO, CA, Sep 09, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Thomson Reuters and BioCentury NewsMakers in the Biotech Industry
Toggle Summary Cytokinetics to Present Phase IIa Clinical Trials Data on Omecamtiv Mecarbil at the 2009 Heart Failure Society of America Annual Meeting
SOUTH SAN FRANCISCO, CA, Sep 08, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to two Phase IIa clinical trials evaluating omecamtiv mecarbil (formerly CK-1827452), one in stable heart failure patients and one in patients with ischemic
Toggle Summary Cytokinetics Presents Phase IIa Clinical Trials Data Relating to Omecamtiv Mecarbil at the European Society of Cardiology Congress 2009
Results Provide Support for Further Clinical Development of Novel Cardiac Muscle Myosin Activator for the Potential Treatment of Heart Failure SOUTH SAN FRANCISCO, CA, Aug 31, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data from two Phase IIa
Toggle Summary Cytokinetics to Present Phase IIa Clinical Trials Data on Omecamtiv Mecarbil at the European Society of Cardiology Congress 2009
SOUTH SAN FRANCISCO, CA, Aug 24, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to two Phase IIa clinical trials evaluating omecamtiv mecarbil (formerly CK-1827452), one in stable heart failure patients and one in patients with ischemic
Toggle Summary Cytokinetics, Incorporated Reports Second Quarter 2009 Financial Results
Quarterly Highlights Include Amgen's Exercise of Option to Company's Cardiac Contractility Program and Initiation of a Phase I Clinical Trial With CK-2017357; Omecamtiv Mecarbil Adopted as Generic Name for CK-1827452 SOUTH SAN FRANCISCO, CA, Jul 29, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics,
Toggle Summary Cytokinetics to Announce Second Quarter Results on July 29, 2009
SOUTH SAN FRANCISCO, CA, Jul 22, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report second quarter results on Wednesday, July 29, 2009 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior management will
Toggle Summary Cytokinetics Announces the Initiation of a First-Time-in-Humans, Phase I Clinical Trial of CK-2017357
First Drug Candidate From Cytokinetics' Fast Skeletal Muscle Activator Program to Enter Clinical Trials SOUTH SAN FRANCISCO, CA, Jun 18, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has initiated a first-time-in-humans, Phase I clinical
Toggle Summary Cytokinetics to Present at the Eighth Annual Needham Life Sciences Conference
SOUTH SAN FRANCISCO, CA, Jun 04, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Sharon Barbari, Senior Vice President, Finance and Chief Financial Officer, is scheduled to present a corporate update at the 8th Annual Needham Life Sciences Conference
Toggle Summary Cytokinetics Presents Clinical Data Relating to Ispinesib in Patients With Metastatic Breast Cancer at the 2009 Annual Meeting of the American Society of Clinical Oncology
New Dosing Schedule Suggests Potential Amplified Clinical Activity of This Novel KSP Inhibitor SOUTH SAN FRANCISCO, CA, Jun 02, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a poster presentation summarizing interim data from the Phase I portion of
Toggle Summary Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 Presented at the 2009 Annual Meeting of the American Society of Clinical Oncology
Preclinical Data Highlights Potential Application for Novel Mechanism Drug Candidate in Pediatric Cancers SOUTH SAN FRANCISCO, CA, Jun 01, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a poster presentation summarizing non-clinical data for
Toggle Summary Cytokinetics Announces Presentations of Data From Phase IIa Clinical Trials of CK-1827452 at the 2009 Heart Failure Congress of the European Society of Cardiology
Results From Two Completed Studies Support Further Clinical Development SOUTH SAN FRANCISCO, CA, Jun 01, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data from two Phase IIa clinical trials evaluating CK-1827452 were presented in the Late Breaking
Toggle Summary Cytokinetics Presents Clinical Data Relating to SB-743921 in Patients With Non-Hodgkin or Hodgkin Lymphoma at the 2009 Annual Meeting of the American Society of Clinical Oncology
Potential Amplified Efficacy Signal Observed With Greater Dose-Density on New Schedule SOUTH SAN FRANCISCO, CA, May 30, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a poster presentation summarizing interim data from the Phase I portion of a Phase
Toggle Summary Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
Cytokinetics Receives Exercise Fee of $50 Million; Cytokinetics to Host a Conference Call Tuesday, May 26, 2009 at 9 AM ET SOUTH SAN FRANCISCO, CA and THOUSAND OAKS, CA, May 26, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics Incorporated (NASDAQ: CYTK) and Amgen Inc.
Toggle Summary Cytokinetics to Hold a Conference Call Tuesday, May 26, 2009 at 9 AM Eastern Time to Discuss Its Collaboration and Option Agreement With Amgen
SOUTH SAN FRANCISCO, CA, May 26, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) is scheduled to hold a conference call on Tuesday, May 26, 2009 at 9 a.m. Eastern Time to discuss its Collaboration and Option Agreement with Amgen relating to its cardiac contractility
Toggle Summary Cytokinetics to Present Phase IIa Clinical Trials Data on CK-1827452 at the 2009 Heart Failure Congress of the European Society of Cardiology
Results to Be Presented at Late Breaking Trials Session SOUTH SAN FRANCISCO, CA, May 22, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to two Phase IIa clinical trials evaluating CK-1827452, one in stable heart failure patients and one
Toggle Summary Cytokinetics Announces Registered Direct Common Stock Offering of $14.0 Million
SOUTH SAN FRANCISCO, CA, May 19, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it has entered into definitive agreements with certain of its existing institutional shareholders to sell an aggregate of 7,106,600 units, with each unit consisting of (i)
Toggle Summary Cytokinetics Announces Clinical and Non-Clinical Data Relating to SB-743921, Ispinesib and GSK-923295 to Be Presented at the 2009 Annual Meeting of the American Society of Clinical Oncology
SOUTH SAN FRANCISCO, CA, May 14, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three abstracts summarizing clinical and non-clinical data are scheduled to be presented as poster presentations at the 2009 Annual Meeting of the American Society of
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, CA, May 14, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that its Annual Meeting of Stockholders will be held on Thursday, May 21, 2009 at 10:00 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South
Toggle Summary Cytokinetics to Present at the Eighth Annual JMP Securities Research Conference
SOUTH SAN FRANCISCO, CA, May 12, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 8th Annual JMP Securities Research Conference Tuesday, May 19,
Toggle Summary Cytokinetics Presents Non-Clinical Data From Its Smooth Muscle Contractility Program at the American Society of Hypertension 24th Annual Scientific Meeting and Exposition
SOUTH SAN FRANCISCO, CA, May 07, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a poster summarizing non-clinical data from its smooth muscle contractility program was presented at the American Society of Hypertension 24th Annual Scientific Meeting
Toggle Summary Cytokinetics to Present at the Bank of America and Merrill Lynch Healthcare Conference
SOUTH SAN FRANCISCO, CA, May 05, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 12th Annual Bank of America and Merrill Lynch Healthcare
Toggle Summary Cytokinetics Announces Non-Clinical Data Relating to Its Smooth Muscle Contractility Program to Be Presented at the American Society of Hypertension 24th Annual Scientific Meeting and Exposition
SOUTH SAN FRANCISCO, CA, May 04, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing non-clinical data regarding its smooth muscle contractility program is scheduled to be presented as a poster presentation at the American Society
Toggle Summary Cytokinetics, Incorporated Reports First Quarter 2009 Financial Results
Quarterly Highlights Include Delivery of Clinical Data Package to Amgen Required to Inform Option Exercise and Presentation of Final Data for CK-1827452 in Stable Heart Failure Patients SOUTH SAN FRANCISCO, CA, Apr 30, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK)
Toggle Summary Cytokinetics to Announce First Quarter Results on April 30, 2009
SOUTH SAN FRANCISCO, CA, Apr 23, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report first quarter results on Thursday, April 30, 2009 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior management will
Toggle Summary Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 Presented at the 2009 American Association of Cancer Research Annual Meeting
Results Support Ongoing Phase I Clinical Trial of Novel CENP-E Inhibitor SOUTH SAN FRANCISCO, CA, Apr 22, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two abstracts containing non-clinical data relating to GSK-923295, a novel inhibitor of
Toggle Summary Cytokinetics Announces Non-Clinical Data Relating to CK-2017357 Presented at the 2009 Experimental Biology Conference
Mechanistic Data Support Progression of Novel Skeletal Muscle Activator Into Clinical Development in 2009 SOUTH SAN FRANCISCO, CA, Apr 20, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a poster containing data relating to CK-2017357, a fast skeletal
Toggle Summary Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to be Presented at the 2009 American Association of Cancer Research Annual Meeting
SOUTH SAN FRANCISCO, CA, Apr 15, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two abstracts containing non-clinical data relating to GSK-923295, a novel inhibitor of centromere-associated protein E (CENP-E), are scheduled to be presented at the
Toggle Summary Cytokinetics Announces Non-Clinical Data Relating to CK-2017357 to Be Presented at the 2009 Experimental Biology Conference
SOUTH SAN FRANCISCO, CA, Apr 13, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a poster containing data on CK-2017357, a fast skeletal muscle troponin activator, is scheduled to be presented at the 2009 Experimental Biology Conference to be held
Toggle Summary Cytokinetics Announces Final Phase IIa Clinical Trial Data for CK-1827452 Presented at the 2009 Annual Scientific Sessions of the American College of Cardiology
CK-1827452 Demonstrates Improvements in Systolic Performance and Hemodynamics in Stable Heart Failure Patients; Company to Hold Investor Teleconference to Discuss Final Results at 8:30 a.m. ET Today SOUTH SAN FRANCISCO, CA, Mar 30, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated
Toggle Summary Cytokinetics Announces Clinical Trials Data Relating to CK-1827452 to be Presented at the 2009 Annual Scientific Sessions of the American College of Cardiology
Company Plans Investor Teleconference to Discuss Final Results SOUTH SAN FRANCISCO, CA, Mar 23, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for CK-1827452 are scheduled to be presented at the 2009 Annual
Toggle Summary Cytokinetics Announces Non-Clinical Data Relating to Its Skeletal Muscle Contractility Program Presented at the Biophysical Society 53rd Annual Meeting
SOUTH SAN FRANCISCO, CA, Mar 04, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three abstracts summarizing non-clinical data regarding its skeletal muscle contractility program were presented as poster presentations at the Biophysical Society 53rd
Toggle Summary Cytokinetics Delivers Clinical Trials Data to Inform Amgen's Option Relating to CK-1827452
SOUTH SAN FRANCISCO, CA, Feb 25, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Inc. (NASDAQ: CYTK) announced today that it has delivered to Amgen Inc. the data from the Phase I and IIa clinical trials conducted with CK-1827452 that it believes is required to inform Amgen's exercise of its option
Toggle Summary Cytokinetics Announces Non-Clinical Data Relating to Its Skeletal Muscle Contractility Program to Be Presented at the Biophysical Society 53rd Annual Meeting
SOUTH SAN FRANCISCO, CA, Feb 23, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three abstracts summarizing non-clinical data regarding its skeletal muscle contractility program are scheduled to be presented as poster presentations at the Biophysical
Toggle Summary Cytokinetics Announces Addition to Board of Directors
Company Announces Appointment of Dr. John Henderson SOUTH SAN FRANCISCO, CA, Feb 19, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Dr. John T. Henderson has been appointed to the company's Board of Directors. Dr.
Toggle Summary Cytokinetics, Incorporated Reports Fourth Quarter and Year End 2008 Financial Results
Company Updates Progress on Programs and Provides Milestones and Financial Guidance for 2009; Recent Highlights Include Presentation of Clinical Trials Data for CK-187452 and Expansion of Muscle Contractility Pipeline SOUTH SAN FRANCISCO, CA, Feb 10, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics,
Toggle Summary Cytokinetics to Announce Fourth Quarter and Year End Results on February 10, 2009
SOUTH SAN FRANCISCO, CA, Feb 03, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report fourth quarter and year end results on Tuesday, February 10, 2009 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior
Toggle Summary Cytokinetics to Present at BIO CEO and Investor Conference
SOUTH SAN FRANCISCO, CA, Feb 02, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the BIO CEO and Investor Conference on Tuesday, February 10th at
Toggle Summary Cytokinetics Announces Updates Relating to Muscle Biology Research and Non-Clinical Development Programs
IND Filing Planned for CK-2017357 in 2009 -- Second Skeletal Muscle Troponin Activator Selected for Development; Smooth Muscle Myosin Inhibitor Selected for Development -- Potential Drug Candidate to Enter IND-Enabling Studies in 2009 SOUTH SAN FRANCISCO, CA, Jan 12, 2009 (MARKET WIRE via COMTEX
Toggle Summary Cytokinetics to Present at the 27th Annual JPMorgan Healthcare Conference
SOUTH SAN FRANCISCO, CA, Jan 09, 2009 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 27th Annual JPMorgan Healthcare Conference on
Toggle Summary Cytokinetics Retains Development and Commercialization Rights to Ispinesib and SB-743921
GlaxoSmithKline Continues to Lead Development Activities for GSK-923295 SOUTH SAN FRANCISCO, CA, Dec 23, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) and GlaxoSmithKline (GSK) announced today that GSK has informed Cytokinetics that it will not exercise its
Toggle Summary Cytokinetics Announces Phase IIa Clinical Trial Results Relating to CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina
Safety Data Support Progression to Phase IIb Development Program; Update on Amgen Option and CK-1827452 Clinical Trials Program SOUTH SAN FRANCISCO, CA, Dec 18, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today top-line results from a Phase IIa
Toggle Summary Cytokinetics Announces Clinical and Preclinical Data Regarding Ispinesib Presented at the 31st Annual San Antonio Breast Cancer Symposium
SOUTH SAN FRANCISCO, CA, Dec 12, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two posters, one summarizing interim Phase I clinical trial data evaluating ispinesib in the treatment of breast cancer and another containing preclinical
Toggle Summary Cytokinetics Announces Clinical Trial Data Regarding SB-743921 Presented at the 2008 Annual Meeting of American Society of Hematology
SOUTH SAN FRANCISCO, CA, Dec 08, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing interim Phase I data from a clinical trial evaluating SB-743921 in patients with lymphoma was presented as a poster at the 2008
Toggle Summary Cytokinetics Announces Preclinical and Clinical Trial Data Regarding Ispinesib to Be Presented at the 31st Annual San Antonio Breast Cancer Symposium
SOUTH SAN FRANCISCO, CA, Dec 05, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two abstracts, one summarizing interim clinical trial data evaluating ispinesib and another regarding preclinical data for ispinesib, are scheduled to be
Toggle Summary Cytokinetics to Present at the RBC Capital Markets Healthcare Conference
SOUTH SAN FRANCISCO, CA, Dec 03, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Sharon Barbari, Senior Vice President, Finance and Chief Financial Officer, is scheduled to participate in a panel discussion entitled "Replacing The
Toggle Summary Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2008 American Society of Hematology Annual Meeting and Exposition
SOUTH SAN FRANCISCO, CA, Dec 01, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing interim clinical trial data evaluating SB-743921 is scheduled to be presented as a poster presentation at the 2008 American Society
Toggle Summary Cytokinetics Files Replacement Shelf Registration Statement
SOUTH SAN FRANCISCO, CA, Nov 10, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it has filed a shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission (SEC).
Toggle Summary Cytokinetics Announces Data From a Clinical Trial of CK-1827452 in Stable Heart Failure Patients Presented at the 2008 Scientific Sessions of the American Heart Association
Novel Drug Candidate Demonstrates Statistically Significant Increases in Systolic Ejection Time, Stroke Volume, Fractional Shortening, Cardiac Output and Ejection Fraction SOUTH SAN FRANCISCO, CA, Nov 10, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK)
Toggle Summary Cytokinetics to Present at November Healthcare Conferences
SOUTH SAN FRANCISCO, CA, Nov 05, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present corporate updates at two investor conferences in November: Mr.
Toggle Summary Cytokinetics Announces Clinical Trials Data Relating to CK-1827452 to Be Presented at the 2008 Scientific Sessions of the American Heart Association
Interim Analysis in an Ongoing Clinical Trial in Patients With Stable Heart Failure to Be Presented SOUTH SAN FRANCISCO, CA, Nov 03, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for
Toggle Summary Cytokinetics, Incorporated Reports Third Quarter 2008 Financial Results
Company Updates Progress on Clinical Programs and Comments on Restructuring; Recent Highlights Include Presentation of Clinical Data at HFSA and ASCO Breast Cancer Symposium SOUTH SAN FRANCISCO, CA, Oct 30, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK),
Toggle Summary Cytokinetics to Announce Third Quarter Results on October 30, 2008
SOUTH SAN FRANCISCO, CA, Oct 23, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report third quarter results on Thursday, October 30, 2008 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior
Toggle Summary Cytokinetics Announces Data Relating to GSK-923295 and SB-743921 Presented at the 2008 EORTC-NCI-AACR International Symposium
SOUTH SAN FRANCISCO, CA, Oct 23, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three posters containing data on GSK-923295, an inhibitor of centromere-associated protein E (CENP-E), and one poster containing data on SB-743921, an
Toggle Summary Cytokinetics Announces Clinical Trials Data Relating to CK-1827452 Presented at the 12th Annual Scientific Meeting of the Japanese Heart Failure Society
SOUTH SAN FRANCISCO, CA, Oct 20, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for CK-1827452 were presented during a Special Program at the 12th Annual Scientific Meeting of the Japanese
Toggle Summary Cytokinetics Announces Data Relating to GSK-923295 and SB-743921 to Be Presented at the 2008 EORTC-NCI-AACR International Symposium
SOUTH SAN FRANCISCO, CA, Oct 15, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that four posters containing data on GSK-923295, an inhibitor of centromere-associated protein E (CENP-E) and data on SB-743921, an inhibitor of kinesin spindle
Toggle Summary Cytokinetics Announces Clinical Trials Data Relating to CK-1827452 to Be Presented at the 12th Annual Scientific Meeting of the Japanese Heart Failure Society
Interim Analysis in an Ongoing Clinical Trial in Patients With Stable Heart Failure to Be Presented SOUTH SAN FRANCISCO, CA, Oct 10, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for
Toggle Summary Cytokinetics to Present at JMP Securities Healthcare Focus Conference
SOUTH SAN FRANCISCO, CA, Sep 30, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Third Annual JMP Securities Healthcare Focus
Toggle Summary Cytokinetics Announces Clinical Trials Data Relating to CK-1827452 Presented at the 2008 Annual Heart Failure Society of America Conference
Interim Analysis of Ongoing Phase IIa Clinical Trial Demonstrates Statistically Significant Correlations Between Measures of Cardiac Systolic Performance and CK-1827452 Plasma Concentrations SOUTH SAN FRANCISCO, CA, Sep 24, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated
Toggle Summary Cytokinetics Announces Clinical Trials Data Relating to CK-1827452 to Be Presented at the 2008 Annual Heart Failure Society of America Conference
Interim Analysis in an Ongoing Clinical Trial in Patients With Stable Heart Failure to Be Presented in Late Breaking Session SOUTH SAN FRANCISCO, CA, Sep 17, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a Late Breaking oral
Toggle Summary Cytokinetics Announces Strategic Realignment of Workforce and Operations
Focused Research to Muscle Biology Expected to Result in Expanded Development Portfolio and Decreased Spending in 2009 SOUTH SAN FRANCISCO, CA, Sep 16, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced plans to realign its workforce and operations in
Toggle Summary Cytokinetics Announces Interim Clinical Trial Data Relating to Ispinesib Presented at the 2008 ASCO Breast Cancer Symposium
Clinical Activity Observed in the Phase I Portion of Clinical Trial Evaluating Ispinesib as First-Line Monotherapy on Alternative Dosing Schedule SOUTH SAN FRANCISCO, CA, Sep 08, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced that data from its
Toggle Summary Cytokinetics Announces the Initiation of Third Phase IIa Clinical Trial of CK-1827452
First Patient Dosed in a Clinical Trial Evaluating the Potential Effects of CK-1827452 on Cardiac Function, Hemodynamics and Oxygen Consumption in Patients With Stable Heart Failure SOUTH SAN FRANCISCO, CA, Sep 05, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ:
Toggle Summary Cytokinetics Announces Interim Clinical Trial Data Relating to CK-1827452 Presented at the European Society of Cardiology Congress 2008
Statistically Significant Improvements in Measures of Cardiac Function Observed in Patients With Stable Heart Failure SOUTH SAN FRANCISCO, CA, Sep 02, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that additional interim results from an
Toggle Summary Cytokinetics Announces Clinical Trials Data Relating to Ispinesib to Be Presented at the 2008 ASCO Breast Cancer Symposium
Additional Results From Ongoing Phase I/II Clinical Trial in Patients With Locally Advanced or Metastatic Breast Cancer SOUTH SAN FRANCISCO, CA, Aug 29, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data from an ongoing Phase I/II
Toggle Summary Cytokinetics to Present at the NewsMakers in the Biotechnology Industry Conference
SOUTH SAN FRANCISCO, CA, Aug 28, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Thomson Reuters and BioCentury NewsMakers in the
Toggle Summary Cytokinetics Announces Completion of Interim Safety Analysis in Ongoing Phase IIa Clinical Trial of CK-1827452
Safety Data From First Cohort Deemed Acceptable to Allow Progression to Second Cohort in Patients With Ischemic Cardiomyopathy and Angina No Serious Adverse Events Observed SOUTH SAN FRANCISCO, CA, Aug 27, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK)
Toggle Summary Cytokinetics Announces Clinical Trials Data Relating to CK-1827452 to Be Presented at the European Society of Cardiology Congress 2008
Additional Results From Interim Analysis in Ongoing Clinical Trial in Stable Heart Failure Patients SOUTH SAN FRANCISCO, CA, Aug 25, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that additional interim results from an ongoing Phase IIa
Toggle Summary Cytokinetics, Incorporated Reports Second Quarter 2008 Financial Results
Company Updates Progress on Clinical Programs and Reports on Increased Research Focus; Recent Highlights Include Presentation of Clinical Data at Heart Failure Congress and ASCO SOUTH SAN FRANCISCO, CA, Jul 31, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK),
Toggle Summary Cytokinetics to Announce Second Quarter Results on July 31, 2008
SOUTH SAN FRANCISCO, CA, Jul 24, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it will report second quarter results on Thursday, July 31, 2008 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior management will
Toggle Summary Cytokinetics Announces Clinical Data Regarding Ispinesib in Combination With Capecitabine
Drug Candidate Demonstrates Acceptable Safety and Tolerability in Phase Ib Trial SOUTH SAN FRANCISCO, CA, Jun 30, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the results of a Phase Ib clinical trial designed to evaluate ispinesib in
Toggle Summary Cytokinetics Announces Third Extension of Research Term Under Collaboration With GlaxoSmithKline
SOUTH SAN FRANCISCO, CA, Jun 19, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced that it has agreed to extend the research term under its strategic alliance with GlaxoSmithKline (GSK) to continue research activities focused towards the mitotic
Toggle Summary Cytokinetics Announces Late Breaking Trials Presentation Relating to CK-1827452 at the 2008 Heart Failure Congress of the European Society of Cardiology
Novel Cardiac Myosin Activator Demonstrates Clinically Relevant and Statistically Significant Increases in Indices of Ventricular Function; Investor Lunch and Webcast Scheduled for Today SOUTH SAN FRANCISCO, CA, Jun 16, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated
Toggle Summary Cytokinetics Provides Updates From Phase I Clinical Trials of CK-1827452
Results From Three Trials Support Ongoing Clinical Development Program SOUTH SAN FRANCISCO, CA, Jun 13, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced results from three Phase I clinical trials evaluating CK-1827452, a novel cardiac myosin
Toggle Summary Cytokinetics to Present Clinical Data on CK-1827452, a Selective Cardiac Myosin Activator, at the 2008 Heart Failure Congress of the European Society of Cardiology
Interim Phase IIa Clinical Trial Results to Be Presented at a Late Breaking Trials Session on June 16th; Investor Lunch and Webcast Scheduled SOUTH SAN FRANCISCO, CA, Jun 09, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that interim results
Toggle Summary Cytokinetics Announces Clinical Trial Data Related to SB-743921 Presented at the 10th International Conference on Malignant Lymphoma
Novel KSP Inhibitor Demonstrates Favorable Tolerability and Activity on an Every-Other-Week Dosing Schedule in Ongoing Clinical Trial SOUTH SAN FRANCISCO, CA, Jun 05, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing
Toggle Summary Cytokinetics to Present at Needham Healthcare Conference
SOUTH SAN FRANCISCO, CA, Jun 04, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at Needham and Company's Seventh Annual Biotechnology &
Toggle Summary Cytokinetics Announces Clinical Trials Data Presented at the 2008 Annual Meeting of the American Society of Clinical Oncology
Company Provides Updates on Progress of Clinical Trials With Ispinesib and SB-743921 SOUTH SAN FRANCISCO, CA, Jun 03, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three abstracts summarizing data from clinical trials relating to its
Toggle Summary Cytokinetics Announces Clinical Trials Data Related to SB-743921 to Be Presented at the 10th International Conference on Malignant Lymphoma
SOUTH SAN FRANCISCO, CA, May 29, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing data from its Phase I/II clinical trial evaluating its drug candidate SB-743921 is planned to be presented at the 10th International
Toggle Summary Cytokinetics Announces Addition to Board of Directors
Company Announces Appointment of Denise Gilbert, Ph.D. SOUTH SAN FRANCISCO, CA, May 16, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that effective May 14, 2008, Denise M. Gilbert, Ph.D. has been appointed to the company's Board of
Toggle Summary Cytokinetics Announces Clinical Trials Data to be Presented at the 2008 Annual Meeting of the American Society of Clinical Oncology
SOUTH SAN FRANCISCO, CA, May 16, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three abstracts summarizing data from clinical trials relating to its oncology programs are planned to be presented at the 2008 Annual Meeting of the
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, CA, May 15, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that its Annual Meeting of Stockholders will be held on Thursday, May 22, 2008 at 10:00 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway
Toggle Summary Cytokinetics to Present at May Healthcare Conferences
SOUTH SAN FRANCISCO, CA, May 12, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that members of its senior management team are scheduled to present corporate updates at two investor conferences in May: Sharon Surrey-Barbari, Senior Vice
Toggle Summary Cytokinetics, Incorporated Reports First Quarter 2008 Financial Results
Company Updates Progress on Cardiovascular and Oncology Programs; Recent Highlights Include Initiation of Second Phase IIa Clinical Trial of CK-1827452, Opening Enrollment of Third Phase IIa Trial for CK-1827452, and Expansion of Development Portfolio SOUTH SAN FRANCISCO, CA, Apr 29, 2008 (MARKET
Toggle Summary Cytokinetics Announces the Initiation of Second Phase IIa Clinical Trial of CK-1827452
First Patient Dosed in a Clinical Trial Evaluating the Safety of CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina SOUTH SAN FRANCISCO, CA, Apr 29, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the initiation of its second Phase
Toggle Summary Cytokinetics to Announce First Quarter Results on April 29, 2008
SOUTH SAN FRANCISCO, CA, Apr 22, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it will report first quarter results on Tuesday, April 29, 2008 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior management will
Toggle Summary Cytokinetics Announces Selection of Development Compound That Activates the Skeletal Sarcomere
Fifth Development Compound Arising From Research Activities Focused to Cytoskeletal Pharmacology SOUTH SAN FRANCISCO, CA, Apr 17, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the selection of a development compound that is directed towards
Toggle Summary Cytokinetics Announces Data Relating to GSK-923295 Presented at the 2008 American Association of Cancer Research Annual Meeting
SOUTH SAN FRANCISCO, CA, Apr 16, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three abstracts relating to GSK-923295 were presented at the 2008 American Association of Cancer Research (AACR) Annual Meeting held this week in San Diego,
Toggle Summary Cytokinetics Announces Non-Clinical and Clinical Data Relating to GSK-923295 to Be Presented at the 2008 American Association of Cancer Research Annual Meeting
SOUTH SAN FRANCISCO, CA, Apr 07, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three abstracts containing non-clinical and clinical data will be presented at the 2008 American Association of Cancer Research (AACR) Annual Meeting to be
Toggle Summary Cytokinetics Announces Presentation of Non-Clinical Data Relating to CK-1827452 at the 2008 Annual Scientific Sessions of the American College of Cardiology
Novel Drug Candidate Demonstrates Increase in Left Ventricular Function With No Increase in Myocardial Oxygen Consumption in Canine Model SOUTH SAN FRANCISCO, CA, Mar 31, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract related
Toggle Summary Cytokinetics to Present Non-Clinical Data on Cardiac Myosin Activator CK-1827452 at the 2008 Annual Scientific Sessions of the American College of Cardiology
SOUTH SAN FRANCISCO, CA, Mar 25, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract related to non-clinical data for CK-1827452, a novel small molecule activator of cardiac myosin, will be presented at the 2008 Annual Scientific
Toggle Summary Cytokinetics Announces Positive Results From an Interim Analysis of an Ongoing Phase IIa Clinical Trial of CK-1827452 in Patients With Stable Heart Failure
Novel Cardiac Myosin Activator Demonstrates Statistically Significant Increases in Indices of Cardiac Ventricular Function; Data to Be Presented at the Heart Failure Congress in Milan in June; Company to Host Investor Breakfast on March 31st SOUTH SAN FRANCISCO, CA, Mar 24, 2008 (MARKET WIRE via
Toggle Summary Cytokinetics to Present at BIO CEO and Investor Conference
SOUTH SAN FRANCISCO, CA, Feb 05, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the BIO CEO and Investor Conference at the Waldorf
Toggle Summary Cytokinetics, Incorporated Reports Fourth Quarter and Year End 2007 Financial Results
Company Updates Progress on Programs and Provides Milestones and Financial Guidance for 2008; Company Announces Transition of Founder and Executive Chairman SOUTH SAN FRANCISCO, CA, Jan 31, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) reported revenues
Toggle Summary Cytokinetics to Announce Fourth Quarter and Year End Results on January 31, 2008
SOUTH SAN FRANCISCO, CA, Jan 24, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it will report fourth quarter and full year 2007 results on Thursday, January 31, 2008 at 4:00 p.m. Eastern Time.
Toggle Summary Cytokinetics Announces the Initiation of a Phase I/II Clinical Trial for Ispinesib in Metastatic Breast Cancer
Clinical Trial Designed to Evaluate Ispinesib as First-Line Monotherapy on an Alternate Dosing Schedule SOUTH SAN FRANCISCO, CA, Dec 31, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced the initiation of an open-label, non-randomized Phase I/II
Toggle Summary Cytokinetics Announces Presentation of Clinical Trial Data Regarding SB-743921 at the 2007 Annual Meeting of American Society of Hematology
Clinical Data Support New Dosing Schedule for SB-743921 and Potential in Hematological Cancers SOUTH SAN FRANCISCO, CA, Dec 10, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a poster summarizing interim data from a Phase I/II clinical
Toggle Summary Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2007 Annual Meeting of American Society of Hematology
SOUTH SAN FRANCISCO, CA, Dec 03, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing interim clinical trial data evaluating SB-743921 is scheduled to be presented as a poster presentation at the 2007 Annual Meeting of
Toggle Summary Cytokinetics Announces Presentation of Scientific Poster at the 47th Annual American Society of Cell Biology Meeting
Scientific Data Support Potential Use of CK-1827452 With Beta-Blockers SOUTH SAN FRANCISCO, CA, Dec 03, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Inc. (NASDAQ: CYTK) announced today that a poster relating to CK-1827452, a novel small molecule activator of cardiac myosin, was
Toggle Summary Cytokinetics Announces Scientific Poster to be Presented at the 47th Annual American Society of Cell Biology Meeting
SOUTH SAN FRANCISCO, CA, Nov 26, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Inc. (NASDAQ: CYTK) announced today that a poster relating to CK-1827452, a novel small molecule activator of cardiac myosin, will be presented at the 47th Annual American Society of Cell Biology (ASCB)
Toggle Summary Cytokinetics, Incorporated Reports Third Quarter 2007 Financial Results
Company Provides Update on Cardiovascular and Oncology Clinical Programs; Company Provides Update on Financial Guidance and Projects Lower Research and Development Spending in 2007 SOUTH SAN FRANCISCO, CA, Oct 31, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ:
Toggle Summary Cytokinetics to Present at November Healthcare Conferences
SOUTH SAN FRANCISCO, CA, Oct 30, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that members of its senior management team are scheduled to present corporate updates at four investor conferences in November: James H.
Toggle Summary Cytokinetics to Announce Third Quarter Results on October 31, 2007
SOUTH SAN FRANCISCO, CA, Oct 24, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it will report third quarter 2007 results on Wednesday, October 31, 2007 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics senior
Toggle Summary Cytokinetics Announces Presentation of Preclinical Data for GSK-923295 at the 2007 AACR-NCI-EORTC International Conference
SOUTH SAN FRANCISCO, CA, Oct 23, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two posters containing preclinical data relating to the mitotic kinesin centromere-associated protein E (CENP-E) and an inhibitor of CENP-E, GSK-923295, were
Toggle Summary Cytokinetics Announces Preclinical Data for GSK-923295 to Be Presented at the 2007 AACR-NCI-EORTC International Conference
SOUTH SAN FRANCISCO, CA, Oct 16, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two posters covering preclinical data from research on the mitotic kinesin centromere-associated protein E (CENP-E) and an inhibitor of CENP-E, GSK-923295,
Toggle Summary Cytokinetics Secures $75 Million Committed Equity Financing Facility
SOUTH SAN FRANCISCO, CA, Oct 15, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it has entered into a Committed Equity Financing Facility (CEFF) with Kingsbridge Capital Limited, a private investment group, in which Kingsbridge has
Toggle Summary Cytokinetics to Present at Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, CA, Sep 18, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company is scheduled to present a corporate update at the following investor conferences: Robert I. Blum, President and Chief Executive Officer, will
Toggle Summary Cytokinetics Announces Presentation of Data on Selective Cardiac Myosin Activator CK-1827452 at the 2007 Annual Heart Failure Society of America Meeting
SOUTH SAN FRANCISCO, CA, Sep 18, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two poster presentations related to CK-1827452, a novel small molecule activator of cardiac myosin, were presented at the 2007 Annual Heart Failure Society
Toggle Summary Cytokinetics Announces the Initiation of a Phase I Clinical Trial for GSK-923295
Third Drug Candidate to Enter Clinical Trials Under Strategic Alliance With GlaxoSmithKline; Initiation of Clinical Trial Triggers Milestone Payment to Cytokinetics SOUTH SAN FRANCISCO, CA, Aug 14, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced
Toggle Summary Cytokinetics, Incorporated Reports Second Quarter 2007 Financial Results
Company Provides Update on Cardiovascular and Oncology Clinical Programs SOUTH SAN FRANCISCO, CA, Jul 31, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) reported revenues from research and development collaborations of $3.2 million for the second quarter of
Toggle Summary Cytokinetics to Announce Second Quarter Results on July 31, 2007
SOUTH SAN FRANCISCO, CA, Jul 24, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it will report second quarter 2007 results on Tuesday, July 31, 2007 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics senior management
Toggle Summary Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
Results Reported From Three NCI-Sponsored Clinical Trials SOUTH SAN FRANCISCO, CA, Jun 28, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced results from the analyses of three Phase II clinical trials of ispinesib administered as monotherapy, one in
Toggle Summary Cytokinetics Announces Data From Phase II Clinical Trial of Ispinesib in Breast Cancer
Anti-Cancer Activity Supports Further Development of Ispinesib in Additional Breast Cancer Trial SOUTH SAN FRANCISCO, CA, Jun 28, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the final results from a multicenter Phase II clinical trial
Toggle Summary Cytokinetics Announces Second Extension of Research Term Under Collaboration With GlaxoSmithKline
SOUTH SAN FRANCISCO, CA, Jun 19, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced that it has agreed to extend the research term under its strategic alliance with GlaxoSmithKline (GSK) to continue research activities focused towards the mitotic
Toggle Summary Cytokinetics to Present at June Healthcare Conferences
SOUTH SAN FRANCISCO, CA, Jun 05, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences: The Goldman Sachs
Toggle Summary Cytokinetics Announces the Presentation of Clinical Trials Data at the 2007 Annual Meeting of the American Society of Clinical Oncology
SOUTH SAN FRANCISCO, CA, Jun 04, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data from clinical trials relating to its oncology program were presented at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO) in
Toggle Summary Cytokinetics Announces Clinical Trials Data to Be Presented at the 2007 Annual Meeting of the American Society of Clinical Oncology
SOUTH SAN FRANCISCO, CA, May 18, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three abstracts summarizing data from clinical trials relating to its oncology program will be presented at the 2007 Annual Meeting of the American Society
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, CA, May 17, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that its Annual Meeting of Stockholders will be held on Thursday, May 24, 2007 at 10:00 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway
Toggle Summary Cytokinetics to Present at May Healthcare Conferences
SOUTH SAN FRANCISCO, CA, May 11, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that members of its management team are scheduled to present a corporate update at the following investor conferences: Robert I.
Toggle Summary Cytokinetics, Incorporated Reports First Quarter 2007 Financial Results
Company Provides Update on Cardiovascular and Oncology Clinical Programs SOUTH SAN FRANCISCO, CA, Apr 26, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) reported revenues from research and development collaborations of $3.2 million for the first quarter of
Toggle Summary Cytokinetics to Announce First Quarter Results on April 26, 2007
SOUTH SAN FRANCISCO, CA, Apr 19, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it will report first quarter 2007 results on Thursday, April 26, 2007 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics senior management
Toggle Summary Cytokinetics Announces Non-Clinical Trial Data Presented at 2007 AACR Annual Meeting
Data Related to Ispinesib, GSK-923295 and Cytokinetics' Cell-Based Drug Discovery Program Support Advancement of Oncology Programs SOUTH SAN FRANCISCO, CA, Apr 18, 2007 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced the presentation of non-clinical data
Toggle Summary Cytokinetics Announces Initiation of Phase II Clinical Trials Program for CK-1827452
First Patient Dosed in a Phase IIa Clinical Trial Evaluating CK-1827452 in Patients with Stable Heart Failure SOUTH SAN FRANCISCO, Calif., April 12 /PRNewswire-FirstCall/ -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the initiation of a Phase II clinical trials program evaluating
Toggle Summary Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
Four Posters Relating to Company Oncology Programs to be Presented SOUTH SAN FRANCISCO, Calif., April 9 /PRNewswire-FirstCall/ -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that four posters containing non-clinical data will be presented at the 2007 Annual Meeting of the American
Toggle Summary Cytokinetics to Present at BIO CEO and Investor Conference
South San Francisco, CA, February 5, 2007 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a panel discussion and to present a corporate update at the BIO CEO and Investor Conference at the Waldorf
Toggle Summary Cytokinetics, Incorporated Reports Fourth Quarter and Year End 2006 Financial Results
Cytokinetics, Incorporated Reports Fourth Quarter and Year End 2006 Financial Results - Company Provides Update on Cardiovascular and Oncology Programs and 2007 Guidance SOUTH SAN FRANCISCO, CA, January 31, 2007 - Cytokinetics, Incorporated (Nasdaq: CYTK), reported revenues from research and
Toggle Summary Cytokinetics to Announce Fourth Quarter and Year-End Results on January 31, 2007
Cytokinetics to Announce Fourth Quarter and Year-End Results on January 31, 2007 South San Francisco, CA, January 24, 2007 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it will report fourth quarter and year-end 2006 results on Wednesday, January 31, 2007 at 4:00 p.m.
Toggle Summary Cytokinetics Announces Changes to its Executive Management Team and Board of Directors
Cytokinetics Announces Changes to its Executive Management Team and Board of Directors South San Francisco, CA, January 22, 2007 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced the appointment of James H. Sabry, M.D., Ph.D. to the position of Executive Chairman of the Board of Directors and
Toggle Summary Cytokinetics and Amgen Announce Strategic Alliance in Heart Failure
Cytokinetics and Amgen Announce Strategic Alliance in Heart Failure - Collaboration Focused on Discovery, Development and Commercialization of Cardiac Myosin Activators; Amgen Obtains Option on Cytokinetics' Drug Candidate CK-1827452 South San Francisco, CA, January 3, 2007 - Cytokinetics
Toggle Summary Cytokinetics Announces Initiation of Phase II Clinical Trial in Renal Cell Cancer and Phase I Clinical Trial in Pediatric Solid Tumors
Cytokinetics Announces Initiation of Phase II Clinical Trial in Renal Cell Cancer and Phase I Clinical Trial in Pediatric Solid Tumors - Cytokinetics Provides Update on Ispinesib Clinical Trials Progress South San Francisco, CA, December 20, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK)
Toggle Summary Cytokinetics Announces Four Research Posters at the 46th Annual American Society for Cell Biology Meeting
Data Presented Advance Scientific Insights in Cytoskeletal Pharmacology SOUTH SAN FRANCISCO, Calif., Dec. 13 /PRNewswire-FirstCall/ -- Cytokinetics, Incorporated (Nasdaq: CYTK - ) announced today that four posters relating to the company's research activities were presented this week at the 46th
Toggle Summary Cytokinetics Announces Non-Clinical Poster Presentation Regarding Ispinesib at the 2006 Annual Meeting of American Society of Hematology
Cellular Data Demonstrates Therapeutic Potential in the Treatment of Multiple Myeloma SOUTH SAN FRANCISCO, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Cytokinetics, Incorporated (Nasdaq: CYTK - ) announced today that a poster summarizing non-clinical data evaluating ispinesib (SB-715992), a novel
Toggle Summary Cytokinetics to Present at the 2006 RBC Capital Markets Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Cytokinetics, Incorporated (Nasdaq: CYTK - ) announced today that James H. Sabry, M.D., Ph.D., Chief Executive Officer, is scheduled to provide a company update and participate in a panel discussion at the 2006 RBC Capital Markets
Toggle Summary Cytokinetics Announces Non-Clinical Data Regarding Ispinesib to be Presented at the 2006 Annual Meeting of American Society of Hematology
SOUTH SAN FRANCISCO, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Cytokinetics, Incorporated (Nasdaq: CYTK - ) announced today that an abstract summarizing non-clinical data evaluating ispinesib (SB-715992), a novel inhibitor of the mitotic kinesin, kinesin spindle protein (KSP), in in vitro models of
Toggle Summary Cytokinetics Announces Registered Direct Common Stock Offering of $37 Million
SOUTH SAN FRANCISCO, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Cytokinetics, Incorporated (Nasdaq: CYTK - ) announced today that it has entered into definitive agreements with selected institutional investors to purchase approximately $37.0 million of its common stock in a registered direct
Toggle Summary Cytokinetics Announces Four Scientific Posters to be Presented at the 46th Annual American Society of Cell Biology Meeting
South San Francisco, CA, December 5, 2006 - Cytokinetics, Inc. (Nasdaq: CYTK) announced today that four posters relating to its research programs will be presented at the 46th Annual American Society of Cell Biology (ASCB) meeting at the San Diego Convention Center (Halls C, D, E, F and G) in San
Toggle Summary Cytokinetics Announces Oral Bioavailability Results for CK-1827452
South San Francisco, CA, December 1, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that the results from an oral bioavailability study evaluating CK-1827452, a novel cardiac myosin activator, in healthy volunteers support advancement of an oral formulation of CK-1827452 into
Toggle Summary Cytokinetics and GlaxoSmithKline Amend Collaboration and License Agreement
South San Francisco, CA, November 27, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced an amendment of the company's collaboration and license agreement with GlaxoSmithKline (GSK), under which Cytokinetics will assume responsibility for the costs and activities of continued development of
Toggle Summary Cytokinetics to Present at Lazard Capital Markets Life Sciences Conference
South San Francisco, CA, November 20, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that James H. Sabry, M.D., Ph.D., Chief Executive Officer, is scheduled to present a corporate update at the Lazard Capital Markets Third Annual Life Sciences Conference.
Toggle Summary Cytokinetics to Present at Two Upcoming Investor Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., November 9, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK - News) announced today that members of its management team are scheduled to present a corporate update at the following investor conferences: James H. Sabry, M.D., Ph.D., Chief Executive Officer, will present
Toggle Summary Cytokinetics Announces Presentations Relating to Clinical Trial Data on CK-1827452 and its Cardiac Myosin Activator Program at the 2006 Annual American Heart Association Scientific Sessions Meeting
South San Francisco, CA, November 6, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that clinical trial data regarding CK-1827452, and non-clinical data arising from Cytokinetics' cardiovascular program directed towards cardiac myosin activators, will be presented at the 2006
Toggle Summary Cytokinetics, Incorporated Reports Third Quarter 2006 Financial Results
South San Francisco, CA, October 26, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported revenues from research and development collaborations of $0.1 million for the third quarter of 2006. Net loss for the third quarter of 2006 was $14.9 million, or $0.41 per share.
Toggle Summary Cytokinetics to Announce Third Quarter Results on October 26, 2006
South San Francisco, CA, October 19, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it will report third quarter 2006 results on Thursday, October 26, 2006 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics senior management will host a conference call at
Toggle Summary Cytokinetics to Present at BIO InvestorForum 2006
South San Francisco, CA, October 11, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Sharon Surrey-Barbari, Senior Vice President, Finance and Chief Financial Officer, is scheduled to present a corporate update at BIO InvestorForum 2006.
Toggle Summary Cytokinetics Reports Data for Ispinesib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
South San Francisco, CA, October 2, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced results from a planned interim analysis following Stage 1 of a two-stage Phase II clinical trial of ispinesib administered as monotherapy in the treatment of patients with recurrent and/or metastatic head
Toggle Summary Cytokinetics Announces Presentation of Phase I Clinical Trial Data for CK-1827452 During Recent and Late Breaking Trials Session
South San Francisco, CA, September 13, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced positive data today from a first-in-humans Phase I clinical trial evaluating CK-1827452, a novel cardiac myosin activator, administered intravenously. Data from this double-blind, randomized,
Toggle Summary Cytokinetics to Present Clinical and Non-Clinical Data on Selective Cardiac Myosin Activator CK-1827452 at the 2006 Annual Heart Failure Society of America Meeting
South San Francisco, CA, September 5, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that the results of a Phase I clinical trial evaluating CK-1827452, a novel small molecule activator of cardiac myosin, in healthy volunteers, along with non-clinical data arising from
Toggle Summary Cytokinetics Announces Initiation of Phase I Clinical Trial for Oral Administration of CK-1827452
South San Francisco, CA, August 23, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced the initiation of a Phase I clinical trial evaluating the pharmacokinetic profile of CK-1827452 when administered orally to healthy volunteers. CK-1827452 is a direct cardiac myosin activator under
Toggle Summary Cytokinetics to Announce Second Quarter Results on July 27, 2006
South San Francisco, CA, July 27, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported revenues from research and development collaborations of $1.4 million for the second quarter of 2006. Net loss for the second quarter of 2006 was $13.3 million, or $0.37 per share.
Toggle Summary Cytokinetics Announces Positive Phase I Clinical Trial Results for CK-1827452
South San Francisco, CA, June 29, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK - News) announced positive results today from a first-in-humans Phase I clinical trial evaluating CK-1827452, a novel cardiac myosin activator, administered intravenously.
Toggle Summary Cytokinetics Announces the Extension of Research Collaboration with GlaxoSmithKline
Cytokinetics Announces the Extension of Research Collaboration with GlaxoSmithKline South San Francisco, CA, June 19, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced that it has agreed to extend the research term under its strategic alliance with GlaxoSmithKline (GSK) for an additional
Toggle Summary Cytokinetics to Present at Three Upcoming Investor Healthcare Conferences
South San Francisco, CA, June 6, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that members of its management team are scheduled to present a corporate update at the following investor conferences: Cytokinetics to Present at Three Upcoming Investor Healthcare Conferences: * James
Toggle Summary Cytokinetics Announces the Presentation of Clinical Trials Data at the 2006 Annual Meeting of the American Society of Clinical Oncology
South San Francisco, CA, June 5, 2006 - Cytokinetics, Inc. (Nasdaq: CYTK) announced today that data for ispinesib (SB-715992) and SB-743921, from clinical trials being conducted by GlaxoSmithKline (GSK) or the National Cancer Institute (NCI), were presented in oral and poster sessions at the 2006
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
South San Francisco, CA, May 22, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that its Annual Meeting of Stockholders will be held on Thursday, May 25, 2006 at 10:00 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San Francisco, CA.
Toggle Summary Cytokinetics to Present at the Deutsche Bank Securities 31st Annual Health Care Conference
South San Francisco, CA, April 25, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that James H. Sabry, M.D., Ph.D., Chief Executive Officer, is scheduled to present a corporate update at the Deutsche Bank Securities 31st Annual Health Care Conference.
Toggle Summary Cytokinetics Announces Clinical Trials Data to be Presented at the 2006 Annual Meeting of The American Society of Clinical Oncology
South San Francisco, CA, April 24, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that five abstracts summarizing data from clinical trials conducted by GlaxoSmithKline (GSK) or the National Cancer Institute (NCI) evaluating ispinesib (SB-715992) or SB-743921 will be presented at
Toggle Summary Cytokinetics to Announce First Quarter Results on April 27, 2006
South San Francisco, CA, April 20, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it will report first quarter 2006 results on Thursday, April 27, 2006 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics senior management will host a conference call at 4:30
Toggle Summary Cytokinetics to Announce First Quarter Results on April 27, 2006
South San Francisco, CA, April 20, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it will report first quarter 2006 results on Thursday, April 27, 2006 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics senior management will host a conference call at 4:30
Toggle Summary Cytokinetics Announces the Initiation of Phase I/II Clinical Trial for SB-743921
South San Francisco, CA, April 17, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the initiation of a Phase I/II clinical trial of its second Kinesin Spindle Protein (KSP) inhibitor, SB-743921, in patients with non-Hodgkin's lymphoma (NHL).
Toggle Summary Cytokinetics Reports Data for Ispinesib (SB-715992) in Platinum-Sensitive Non-Small Cell Lung Cancer
Cytokinetics Reports Data for Ispinesib (SB-715992) in Platinum-Sensitive Non-Small Cell Lung Cancer - Drug Candidate Does Not Demonstrate Sufficient Anti-Tumor Activity to Proceed to Stage 2 in this Phase II Clinical Trial Drug Candidate Demonstrates Disease Stabilization in 50% of Patients South
Toggle Summary Cytokinetics to Present at the Lehman Brothers Ninth Annual Global Healthcare Conference
Cytokinetics to Present at the Lehman Brothers Ninth Annual Global Healthcare Conference South San Francisco, CA, March 2, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert Blum, President, is scheduled to present a corporate update at the Lehman Brothers Ninth Annual
Toggle Summary Cytokinetics to Present at the Fifth Annual JMP Securities Research Conference
Cytokinetics to Present at the Fifth Annual JMP Securities Research Conference South San Francisco, CA, February 28, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that James H. Sabry, M.D., Ph.D., Chief Executive Officer, is scheduled to present a corporate update at the Fifth
Toggle Summary Cytokinetics to Present at the BIO CEO & Investor Conference 2006
Cytokinetics to Present at the BIO CEO & Investor Conference 2006 South San Francisco, CA, February 8, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that James H. Sabry, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present a corporate update at the BIO CEO
Toggle Summary Cytokinetics, Incorporated Reports Fourth Quarter and Year End 2005 Financial Results
SOUTH SAN FRANCISCO, CA, January 31, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK), reported revenues from research and development collaborations of $2.1 million for the fourth quarter of 2005. Net loss for the fourth quarter of 2005 was $11.1 million or $0.38 per share.
Toggle Summary Cytokinetics to Release Fourth Quarter and Full Year 2005 Results on January 31, 2006
Cytokinetics to Release Fourth Quarter and Full Year 2005 Results on January 31, 2006 South San Francisco, CA, January 24, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it will report fourth quarter and year end 2005 financial results on Tuesday, January 31, 2006 at 4:00
Toggle Summary Cytokinetics Announces $33 Million Financing
Cytokinetics Announces $33 Million Financing South San Francisco, CA, January 18, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced it has obtained commitments to purchase $33.0 million of its common stock in a registered direct offering. Under the terms of the Stock Purchase Agreement,